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ABSTRACT 
 
 
The Protein Arginine Methyltransferase 6 (PRMT6) is an enzyme characterized by a predominant 
nuclear localization and automethylation activity. Until today, very few information are known 
about its function and its substrates. 
To better characterize PRMT6, we looked for new partners and substrates, using the yeast two-
hybrid system. This technique allowed us to discover 36 new partners for this enzyme, 19 of these 
interactions were confirmed with the GST Pull-down assay. Among these partners, 9 resulted to be 
interactors also for HMGA protein, a chromatin architectural factor that has been previously 
demonstrated to be an in vivo substrate of PRMT6. The binding between partners and PRMT6 was 
further assessed in vivo in mammalian cells, and out of nine proteins tested, 7 were confirmed.    
To test whether among the identified partners there were substrates, we performed an in vitro 
methylation assay, and discovered 4 new substrates of this enzyme (Macrophage migration 
inhibitory factor, Human DnaJ homologue, Small nuclear ribonucleoprotein-associated proteins B 
and B’, and Tubulin beta-2A chain). Moreover, we evaluated if the presence of HMGA1a, could 
modulate the methylation activity of PRMT6. We demonstrated that MIF’s methylation was 
enhanced in the presence of HMGA1a protein.  
Furthermore, to evaluate a possible role played by HMGA, MIF, and PRMT6 together, we studied 
the effect of MIF on Cyclin A (CycA) promoter. We choose this reporter because it is known the 
activation effect of HMGA2 protein on this promoter. Our data demonstrated that both MIF and 
PRMT6 could activate this promoter, but the simultaneous presence of these two proteins result in a 
lower activation, suggesting that PRMT6 had a negative effect on MIF function.      
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1. INTRODUCTION 
 
 
1.1 Post translational modifications 
 
Release of a complete polypeptide chain from a ribosome is often not the last chemical step in the 
formation of a protein. Various covalent modifications often occur, either during or after assembly 
of the polypeptide chain. Most proteins undergo co- and/or post-translational modifications (PTMs).   
Knowledge of these modifications is extremely important because they may alter physical and 
chemical properties, folding, conformation distribution, stability, activity, and, consequently, 
function of the proteins. Moreover, the modification itself can act as an added functional group.          
Examples of the biological effects of protein modifications included phosphorylation for signal 
transduction, ubiquitination for proteolysis, attachment of fatty acids for membrane anchoring and 
association, glicosylation for protein half-life, targeting, cell-cell and cell-matrix interactions. 
Consequently, the analysis of proteins and their post-translational modifications is particularly 
important for the study of human disease such as heart disease, cancer, neurodegenerative diseases, 
and diabetes.                 
Characterization of PTMs, although challenging, provides invaluable insight into the cellular 
function underlying etiological processes. Technically, the main challenges of studying post-
translationally modified proteins are the development of specific detection and purification 
methods. Fortunately, these technical obstacles are being overcome with a variety of new and 
refined proteomics technologies. 
Among all PTMs, Lysine and Arginine methylations are the more recent discovered and are 
growing their importance in the cellular context. 
 
 
1.2 Arginine methylation  
 
The primary sequence of a protein is dictated by the genetic code, and functional diversity can then 
be achieved by different post-translational modifications (PTMs). Phosphorylation remains by far 
the most studied and understood PTM; in fact a lot of kinases, phosphatases, and protein containing 
phosphoprotein-interacting modules were identified. In 1967 arginine was shown to contain methyl 
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groups (Paik and Kim, 1967), but only in the recent years this PTM is becoming increasingly 
important.  
Arginine is a positively charged amino acid known to mediate hydrogen bonding and amino-
aromatic interactions. The nitrogens of arginine within polypeptides can be post-translationally 
modified to contain methyl groups, a process termed “arginine methylation”. Protein arginine 
methylation results in the addition of one or two methyl groups to the nitrogen atoms of the 
guanidino group of arginine (Gary and Clarke, 1998). There are three main forms of methylated 
arginine identified in eukaryotes: ω-NG monomehtylarginines (MMA), ω-NG, NG-asymmetric 
dimethylarginines (aDMA), and ω-NG, N’G-symmetric dimethylarginines (sDMA) (Figure 1). 
 
         
 
Figure 1. Various forms of methylation for the Arginine. Arginine residues can be methylated in three different 
forms: ω-NG monomehtylarginines (MMA), ω-NG, NG-asymmetric dimethylarginines (aDMA), and ω-NG, N’G-
symmetric dimethylarginines (sDMA). PRMTs are classified as type I or type II. Both type I and type II generate 
monomethylarginine. The generation of asymmetric dimethylarginine is catalyzed by type I, while the production of 
symmetric dimethylarginine is catalyzed by the type II enzymes.   
 
 
These S-adenosyl-L-methionine-dependent (AdoMet) methylations are carried out by protein 
arginine methyltransferases (PRMT), a family of enzymes found only in eukaryotes (Gary and 
Clarke, 1998). 
 
 
The Protein Arginine Methyltransferase Family 
 
Methyltransferases catalyze the addition of methyl groups to nitrogen, carbon, sulfur, and oxygen 
atoms of small molecules, lipids, protein, and nucleic acids. The methyltransferases family 
encompasses the enzymes that catalyze the protein arginine N-methylation reactions (Gary and 
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Clarke, 1998). To date, nine mammalian protein arginine methyltransferases (PRMT) have been 
identified. They are different in length, but all PRMTs have a core of about 300 amino acids 
residues highly conserved. In this region there are the methyltransferases motifs AdoMet-dependent 
I, post-I, II, and III, responsible for the binding to the S-adenosyl methionine (SAM) and for the 
catalysis of methyl transfer, and the invariant THW loop (Zhang et al., 2000; Weiss et al., 2000; 
Bedford and Richard, 2005). Besides the methyltransferase domain, each PRMT has a N-terminal 
region of different length. Only in PRMT4/CARM1 the variable region is at the C-terminal (Lee et 
al. 2005) (Figure 2). 
 
Figure 2. . Comparison between the mammalian PRMTs known. The family currently contains nine highly related 
members; it is evident the high homology and the conservation of domains. FBXO11 might have arginine 
methyltransferase activity, but is not structurally related to the other PRMTs and required “forced” alignments to 
identify putative signature motifs. PRMT8 and FBXO11 are mouse proteins; the other PRMTs are human. The 
accession numbers for the PRMTs are as follows: hPRMT1: AAF62893; hPRMT2: AAH00727; hPRMT3: AAC39837; 
hCARM1/PRMT4: NP_954592; hPRMT5: AAF04502; hPRMT6: Q96LA8; hHPRT7: NP_061896; mPRMT8: 
DAA01382; hPRMT9: AAH64403; and mFBXO11: AAI28480 (Bedford and Clarke, 2009). 
 
 
PRMTs are classified as either type I, if they generate asymmetric dimethylarginine, or type II 
enzymes, if they catalyze the production of symmetric dimethylarginine. Both types catalyze the 
formation of monomethylarginine as an intermediate. PRMT1, PRMT3, PRMT4/CARM1, PRMT6, 
and PRMT8 are type I enzymes and lead to the production of asymmetric dimethylarginine 
(aDMA), whereas PRMT5, PRMT7, and FBXO11 are type II, and catalyze the formation of 
symmetric dimethylarginine (sDMA). To date, no enzyme has been found that forms both aDMA 
and sDMA derivatives and no activity has been demonstrated for PRMT2 and PRMT9. It is 
worthwhile to note that these activities require validation (Cook et al., 2006; Krause et al., 2007); in 
fact, it now appears that interactions between PRMTs and their binding partners (and presumed 
regulatory subunits) can be transient or permanent, and it is possible that the species with poorly 
defined activities (PRMT2, PRMT7, PRMT9, and FBXO11) require the presence of other subunits 
for catalytic activity (Bedford and Clarke, 2009).   
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PRMT1 is the most abundant enzyme between the type I enzymes, and it was discovered by 
homology with Hmt1/Rmt1, an arginine methyltransferase in yeast (Lin et al., 1996). Its three-
dimensional structure suggests that it is active as a homodimer (Zhang and Cheng, 2003). PRMT2 
was identified by homology with PRMT1 and no activity has been shown for it. PRMT3 was 
discovered for its association with PRMT1 (Scott et al., 1998; Tang et al., 1998), it is located 
exclusively in the cytosol and has a zinc finger domain that appears to anchor it to its substrates 
(Frankel and Clarke, 2000). PRMT4, also referred to as CARM1 (Coactivator associate arginine 
methyltransferase), was identified in the yeast two-hybrid to associate with GRIP1, the p160 steroid 
receptor coactivator (Chen et al., 1999). Its crystal structure was solved by two groups, providing 
insight into its mechanism of action (Troffer-Charlier et al., 2007; Yue et al., 2007); moreover, 
CARM1/PRMT4 loss is not compatible with life (Yadav et al., 2003). PRMT5 was cloned as Jak2 
binding protein (Branscombe et al., 2001; Pollack et al., 1999) and appears to be the major type II 
mammalian enzyme activity; it seems to function in several types of complexes in both cytoplasm 
and the nucleus (Lacroix et al., 2008; Dacwag et al., 2007). PRMT6 and PRMT8 were identified by 
homology (Frankel et al., 2002; Zhang and Cheng, 2003). PRMT6 is a predominantly nuclear 
enzyme characterized by its specificity for distinct methyl-accepting substrates and by its auto-
methylation (Frankel et al., 2002). PRMT7 was identified in a genetic screen looking for suppressor 
elements conferring resistance to a topoisomerase II inhibitor and the evidence for its activity 
remains controversial (Gros et al., 2003). The distribution of PRMT8 is limited mainly to the brain, 
and it is also the only PRMT known to be membrane associated (Lee et al., 2005). PRMT9 is one of 
the most recently discovered and it shows the lowest homology with the others. It was identified 
based on homology with other family members as a product of a gene on human chromosome 
4q31(Lee et al., 2005b). For this reason, and because the PRMT9 designation has also been used for 
the product of the FBXO11 gene in humans on chromosome 2p16 (Cook et al., 2006), PRMT9 is 
also referred as PRMT9(4q31) and it has not been biochemically characterized to date. 
Interestingly, it contains two tetratricopeptide repeats (TPR), motifs which often mediate protein-
protein interactions (Bedford, 2007). FBXO11/PRMT9(2p16) was identified from a “forced” 
alignment of its amino acid sequence to the PRMT family: an in silico screening shows that this 
methyltransferase is present in 4 isoforms that are different in length, but all of them have the 
methyltransferase domains AdoMet-dependent I, post I, II, and III (Cook et al., 2006). In an 
independent study, no activity was reported for the human or worm FBXO11 proteins (Fielenbach 
et al., 2007). Another protein, FBXO10, has been tentatively identified as PRMT11, but no 
biochemical characterization has been done. Further work is needed to determine if this protein can 
be a protein arginine methyltransferase (Krause et al., 2007). 
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Arginine methylation: a reversible process?  
 
An important question under current investigation is whether protein arginine demethylation 
reactions occur to reverse the effect of the modification. Initial studies indicated that methyl groups 
were stable on arginine residues. Recently, two types of enzymes than can remove methyl groups 
from arginine residues were identified. In fact, the peptidyl arginine deiminase PAD4 can eliminate 
methylation on an arginine residue by converting it to citrulline (Cuthbert et al., 2004; Wang et al., 
2004). PAD4 catalyzes the deimination of both arginine and monomethylarginine, but not 
dimethylarginine, to citrulline. But peptidyl arginine deiminases are not true “demethylases”, as 
they do not convert monomethylarginine back to arginine.  
Additionally, a recent work has suggested that the Jumonji domain-containing proteins (JMJD6), 
which was originally identified as a family of lysine demethylases, can demethylate arginine 
residues. Indeed, JMJD6 has been reported to direct regenerate arginine residues from methylated 
histone species (Chang et al., 2007). This is the first example of true arginine demethylase 
identified to date, but it could be possible that other demethylases are yet to be discovered. 
 
 
PRMTs consensus sequences 
 
The main targets of PRMTs seem to be protein that harbor glycine and arginine-rich (GAR) motifs 
(Najbauer et al., 1993). Generally, the type I enzymes recognize GAR-motif containing substrates, 
but for PRMT4/CARM1 there is not obvious motif recognized, in fact, it displays a higher degree 
of specificity and does not methylate GAR motif. On the contrary, the type II enzymes methylate 
isolated arginine residues as well as arginines within GAR motifs. The crystal structures for three 
enzymes that methylates GAR motifs (Hmt1, PRMT1, and PRMT3) are available, and they show a 
very similar core structures (Weiss et al., 2000; Zhang and Cheng, 2003; Zhang et al., 2000). A 
large number of additional substrates have been identified using mass spectrometry approaches 
(Boisvert et al., 2003; Ong et al., 2004; Wu et al., 2004), but in many of these cases the enzyme 
responsible for the arginine methylation remains unknown.           
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Cellular processes regulated by Arginine Methylation 
 
1. Transcriptional Regulation 
Arginine methylation have demonstrated to have both activator and repressor activity in gene 
transcription. It was recognized early on that histones were substrates of methyltransferases (Paik 
and Kim, 1967), and it is now known that histones are substrates of PRMT1, CARM1, and PRMT5 
(McBride and Silver, 2001; Pal et al., 2004). Besides histones methylation, PRMTs are now 
emerging as coregulators of a large number of transcription factors including p53 (An et al., 2004), 
YY1 (Rezai-Zadeh et al., 2003), and NF-kB (Covic et al., 2004).  
Two examples of PRMT transcriptional co-activator are both CARM1/PRMT4, and PRMT6. 
CARM1, in fact, was identified as a nuclear receptor coactivator (Chen et al., 1999) and, in 
transient transfection assay, was shown to enhance steroid hormone receptor-mediated reporter 
gene activation, synergistically with PRMT1 (Bedford and Richard, 2005). On the other hand, in 
luciferase assay, also PRMT6 was shown coactivate the progesterone, glucocorticoid and oestrogen 
receptors in a hormone-dependent manner (Harrison et al., 2010).   
Another example about the activation of the transcription by a PRMT, is the methylation of PRMT1 
on RUNX1 that triggers the dissociation of the transcriptional repressor SIN3A, promoting RUNX1 
transcriptional activity (Zhao et al., 2008). On the contrary, the first demonstration for PRMT 
repressor activity was the synergy between PRMT5 and E2F1 in Ccne1 corepression (Fabbrizio et 
al., 2002), but the mechanism by which PRMT5 mediates transcriptional repression remains to be 
elucidated. Also PRMT6 possesses transcriptional repressor activities; it is the primary enzyme 
responsible for H3R2 methylation in mammalian cells (Guccione et al., 2007; Hyllus et al., 2007; 
Iberg et al., 2008), and this event inhibits H3K4 trimethylation and recruitment of WDR5, a subunit 
of the MLL (mixed lineage leukemia) K4 methyltransferase complex, to histone H3 (Hyllus et al., 
2007). Well-known targets of MLL1 and H3K4 trimethylation are Hox genes (Milne et al., 2002; 
Nakamura et al., 2002; Hughes et al., 2004). It is worthwhile to note that PRMT6 is an important 
negative regulator of a subset of genes that are regulated by H3K4 trimethylation (HOXA5 and 
Cyclin D1). This mechanism reveals an important negative cross-talk between arginine methylation 
and lysine methylation of histones (Hyllus et al., 2007). 
 
2. RNA Processing 
The vast majority of PRMT substrates are associated with RNA (Pahlich et al., 2006). Thus, 
arginine methylation has been implicated in all aspects of RNA metabolism, including mRNA 
transcription, splicing, transport, translation, and turnover. RNA binding proteins (RBPs) represent 
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major targets for PRMTs because most hnRNPs (A1, A2, K, R, and U) harbor GAR motifs. Indeed, 
many RBPs have been identified to be arginine methylated (Hermann et al., 2004). In 2003, Richard 
and co-workers proposed that a possible function for the arginine methylation could be a maturation 
signal (Cote et al., 2003), in fact some RBPs, for example Sam68, are mislocated in their 
hypomethylated state (Lukong an Richard, 2004; Smith et al., 2004). Another event in which 
PRMTs are involved is the splicing of the mRNA. In fact, the efficiency of splicing is reduced in 
hypomethylated nuclear extracts. In addition, PRMT4 and, very recently also PRMT6, were 
identified as a regulator of alternative splicing; in fact, PRMT4 methylates some splicing factors 
like CA150, SAP49, SmB, and U1C (Cheng et al., 2007; Ohkura et al., 2005), and PRMT6 
regulates the alternative splicing of the vascular endothelial growth factor (VEGF) and Syk genes 
(Harrison et al., 2010). 
 
3. Nucleus/Cytoplasm Shuttling 
The first study about the nuclear/cytoplasmic shuttling in which PRMTs are involved was 
conducted in yeast (Shen et al., 1998). RBPs contain GAR motifs and PGM (prolyne-glycine-
methionine) motifs, that are sites for the methylation of PRMT1 and PRMT4, respectively (Cheng 
et al., 2007; Najbauer et al., 1993). It is important to note that some RBPs shuttle between the 
nucleus and the cytoplasm; in yeast cells lacking Hmt1/Rmt1, the primary type 1 PRMT, NpI3 and 
Hrp1, two members of the family of RBPs are blocked in the nucleus (Shen et al., 1998). Instead, in 
mammalian cells, there is a decrease in the nuclear accumulation of the high molecular weight 
forms of fibroblast growth factor-2 (FGF2) after the inhibition of methylation (Pintucci et al., 
1996). This is also the case for Sam68 (Bedford and Richard, 2005). In Xenopus laevis there is a 
similar mechanism: XlPRMT1 methylates the RNA-binding protein CIRP2, and the overexpression 
of the arginine methyltransferase forces hypermethylated CIRP2 out of the nucleus (or blocks its 
return), resulting in its cytoplasmic accumulation (Aoki et al., 2002). Finally, methylation inhibitors 
prevent the nuclear accumulation of the adenovirus 100K protein that, in the methylated form, is 
exclusively nuclear (Iacovides et al., 2007). It is mention to note that some hypomethylated proteins 
accumulate in the nucleus and other in the cytoplasm. The mechanism by which arginine 
methylation regulates the shuttling between nucleus and cytoplasm has not been elucidated.          
 
4. DNA Repair 
In higher eukaryotes, ionizing radiation or replication can induce DNA double strand breaks 
(DSBs) that are then repaired through homologous recombination repair (HRR) or non-homologous 
end joining (NEHJ). In HRR the mammalian Mre11/Rad50/NBS1 (MRN) complex plays an 
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important role; experiments using ASYM25, an aDMA-specific antibody, suggested that at least 
one of the components of the complex is arginine methylated (Boisvert et al, 2003). The only 
protein with GAR motif in its sequence was Mre11, and a study of the 2005 showed that Mre11 was 
a substrate of PRMT1 both in vitro and in vivo (Boisvert et al., 2005). Further investigations 
showed that this methylation regulates the 3’→5’ exonuclease activity of Mre11 on dsDNA. Cells 
treated with a methyltransferase inhibitor followed by the DNA-damaging agent etoposide showed 
the absence of the recruitment of Mre11 to DSBs; in fact, methylation regulates MRN relocalization 
to DSBs (Boisvert et al., 2005b). PRMT1 can also methylate the lysine 79 of the histone H3 in vivo. 
This methylation induces conformational changes in DNA that render methylated lysine accessible 
to 53BP1, another central mediator of the DNA damage checkpoint (Charier et al., 2004; Huyen et 
al., 2004). 
 
 
Regulation of Arginine Methylation 
 
In the cellular context there are several ways to regulate a protein arginine methyltransferase. 
 
1. Some proteins bind PRMTs to regulate their activity. 
PRMTs have been found to interact with proteins and to associate with protein complexes, but 
often, these proteins that are not substrates can alter the methyltransferase activity of the PRMTs 
inhibiting, activating, or changing their substrate specificity (Bedford and Richard, 2005). For 
example, BTG1 and TIS21/BTG2 bind PRMT1 and stimulate its activity toward selected substrates 
(Lin et al., 1996). The activity of PRMT1 can also be regulated in a substrate-dependent manner by 
hCAF1, a BTG-1binding protein, (Robin-Lespinasse et al., 2007). The activity of PRMT3 is 
inhibited, both in vitro reactions and in cell lines, by the binding with the tumour suppressor DAL-1 
(Singh et al., 2004). CARM1 was found in a complex of at least ten proteins called the nucleosomal 
methylation activator complex (NUMAC) in which acquires the ability to methylate nucleosomal 
histone H3; instead, recombinant CARM1 preferentially methylates free histone H3 (Xu et al., 
2004). Also PRMT5 was found in three different protein complexes: in the cytoplasm it was found 
in the “methylosome” where it is involved in the methylation of Sm proteins (Friesen et al., 2001); 
in the nucleus, PRMT5 associated with the regulator of transcriptional elongation, SPT4, and SPT5, 
and pICIn, which is another component of the methylosome (Kwak et al., 2003). Another nuclear 
complex in which PRMT5 is involved, is the binding with BRG and BRM, the hSWI/SNF 
chromatin remodelers. This association enhances PRMT5 methyltransferase activity (Pal et al., 
2004). Also PRMT7 can bind a protein, CTCFL (a protein that associates with the imprinting 
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control region), and this interaction causes an enhancement of its metyltransferase activity (Jelinic 
et al., 2006).  
 
2. PTMs can regulate PRMT activity 
PRMT1, CARM1, PRMT6, and PRMT8 are automethylated, but the functional consequence of this 
methylation remains unknown (Sayegh et al., 2007). CARM1 can also be phosphorylated during 
mitosis by an as yet unidentified kinase, and this event prevents its homodimerization and decreases 
its PRMT activity (Higashimoto et al., 2007). 
 
3. Adjacent PTMs can mask arginine methylation motif 
There is an interplay between the acetylation of the lysine 9 of the histone H3 (H3K9) and the 
PRMT5-mediated methylation of the arginine 8 of the same histone (H3R8): H3K9ac blocks 
H3R8me (Pal et al., 2004). The existence of an H3R8me2a or H3R8me2s mark will in turn block 
the methylation of lysine 9 (H3K9) mediated from G9a (Rathert et al., 2008). In addition, 
H3K4me3 inhibits, but not totally blocks, the PRMT6-mediated methylation of arginine 2 of the 
histone H3 (H3R2) (Guccione et al., 2007; Iberg et al., 2008). H3K4 methylation is also blocked by 
prior H3R2 methylation (Hyllus et al., 2007). 
In addition, it is worthwhile to mention the interplay that has been observed between the 
methylation at lysine 9 of the histone H3 (H3K9) and the phosphorylation at serine 10 of the same 
histone (H3S10) (Rea et al., 2000). The phosphorylation of H3S10 prevents the SUV39H1-
mediated methylation of H3K9. In the same region of histone H3, the K9 acetylation prevents the 
methylation of H3R8 by PRMT5 (Pal et al., 2004). Thus, pre-existing modifications closed to a site 
of methylation can alter the recognition motif of protein methyltransferases.         
 
4. Deimination: from arginine and monomethylarginine to citrulline 
A major group of deiminated proteins are the core histones H2A, H3, and H4 (Nakashima et al., 
2002). The deimination of both arginine and monomethylarginine, but not dimethylarginine, to 
citrulline are catalyzed by peptidyl arginine deiminases (PADs), such as PAD4 (Raijmakers et al., 
2007). Thus, PADs are not demethylases, as they do not convert monomethylarginine back to 
arginine.  
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5. Demethylation 
JMJD6, a Jumonji domain-containing protein, is the first arginine demethylase discovered to date 
(Chang et al., 2007). This enzyme demethylates H3R2me2 and H4R3me3. It is important to note 
that JMJD6 can demethylate both the symmetric and asymmetric forms of H4R3me2.  
The possibility also exists that other types of arginine demethylases have yet to be discovered.   
 
 
Protein-protein interactions regulated by Arginine Methylation 
 
Arginine methylation facilitates the interaction of GAR and PGM motifs with Tudor domain. For 
example, the interaction between the Tudor domains of SMN, SPF30, and TDRD3 with SmB 
requires a symmetric dimethylation of SmB by PRMT5 (Cote and Richard, 2005). The asymmetric 
dimethylation of CA150 by CARM1 also provides a docking site for the SMN Tudor domain 
(Cheng et al., 2007). Thus, motifs harbouring either aDMA or sDMA residues bind a subset of 
proteins containing a Tudor domain. Interestingly, some proteins containing Tudor domain, such as 
JMJD2a, 53BP1, and PHF20 can also bind methyllysine motifs (Kim et al., 2006); thus, there are 
two distinct classes of methyl-binding Tudor domains. To date, the propensity of Tudor domains to 
bind either methylarginine or methyllysine motifs cannot be predicted from their primary sequence.  
Proteins-protein interactions can also be negatively regulated by arginine methylation. For example, 
the methylation of arginine residues that are adjacent to a proline-rich motif can block the binding 
to SH3, but not WW, domain (Bedford et al., 2000). Also the arginine methylation of the p300 
GRIp1-binding domain by CARM1 blocks the protein-protein interaction (Lee et al., 2005c). 
Finally, recent studies revealed that histone H3R2 form critical interactions with an array of H3 N-
terminal tail-binding domains (Taverna et al., 2007). The methylation of the R2 of the histone H3 
blocks the interaction between WDR5 and the histone H3 (Couture at al., 2006) and reduces the 
binding affinity of the CHD1 double chromodomains 4-fold relative to H3K4me3 alone (Flanagan 
et al., 2005). Further work has demonstrated that H3R2 methylation block the binding of most N-
terminal tail-binding domains (chromo, PHD, WD40, and Tudor) (Iberg et al., 2008). 
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Arginine Methylation and diseases 
 
Cancer 
Some common tumours, as prostate and breast, are often hormone dependent. It is known that 
PRMTs are coactivators for nuclear receptors; this fact makes PRMTs good candidates to be over-
expressed in these cancer types. Indeed, it has been found that CARM1 increased expression 
correlates with androgen independence in human prostate carcinoma (Hong et al., 2004) as well as 
in aggressive breast tumours that also express high levels of the oncogenic coactivator AIB1 (El 
Messaoudi et al., 2006). It is important to note that the methylation of AIB1 by CARM1 regulates 
its activity and stability (Feng et al., 2006: Naeem et al., 2007). Importantly, small molecules that 
inhibit both PRMT1 and CARM1 can suppress oestrogen and androgen receptor-mediated 
transcriptional activation (Cheng et al., 2004).  
The transition epithelial-mesenchimal (EMT) in the developmental process plays an important role 
in tumour progression. As a consequence of EMT, cancer cells can migrate and invade much more 
efficiently. The loss of E-cadherin expression is a hallmark of EMT. The transcriptional factor 
SNAIL represses the expression of E-cadherin. A recent report showed that PRMT5 interacts with 
SNAIL and acts as a critical SNAIL co-repressor; in fact, siRNA-mediated PRMT5 knockdown 
results in elevated E-cadherin expression (Hou et al., 2008). In addition, when over-expressed, 
PRMT5 promotes anchorage-independent cell growth (Pal et al., 2004), supporting the notion that 
PRMT5 might be an oncoprotein. In fact, consistent with this idea, in gastric cancer (Kim et al., 
2005), in lymphoma and leukaemia cells (Pal et al., 2007) levels of PRMT5 are elevated. 
 
Cardiovascular disease 
Nitric oxide synthase (NOS) from L-arginine synthesizes nitric oxide (NO) that plays multiple roles 
in cardiovascular system, immune system and that acts as a neurotransmitter in the brain. The 
activity of NOS is inhibited by arginine analogs MMA and aDMA, but not sDMA, leading to 
atherosclerosis (Stuhlinger et al., 2001). PRMTs are responsible for generating NOS inhibitors in 
vivo, in fact these free methylarginine species are generated by the proteolysis of methylated 
proteins. This methylarginine pool size is controlled by dimethylarginine dimethylaminohydrolase 
(DDAH) enzymes, which specifically hydrolyze MMA and aDMA, but not sDMA. In fact an 
imbalance in this pool for PRMT or DDAH dysfunction might increase cardiovascular risk. 
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Viral pathogenesis  
Some different viral proteins have been characterized as PRMTs substrates: herpes simplex virus 1 
nuclear regulatory protein ICP27 (Mears and Rice, 1996), hepatitis C virus protein NS3 (Rho et al., 
2001), Epstein-Barr virus nuclear antigen 2 (EBNA2) (Barth et al., 2003), adenovirus E1B-AP5 
(Kzhyshkowska et al., 2001) and L4-100K (Kzhyshkowska et al., 2004), HIV-1 proteins Rev 
(Invernizzi et al., 2006), Tat (Boulanger et al., 2005), and the nucleocapside (Invernizzi et al., 
2007). All of these viral proteins are methylated and contain GAR-motifs that are targeted for 
methylation by either PRMT1 or PRMT6. Using methyltransferase inhibitors, it was demonstrated 
that methylation contributes to maximal virus infectivity in an HIV-1 infection cell culture model 
(Willemsen et al., 2006) and is critical for productive adenovirus infection (Iacovides et al., 2007). 
Thus, the methylation of viral proteins may provide a means by which they can enhance their 
complexity and expand their repertoire of interacting partners.  
 
Multiple sclerosis 
It is of note that the nervous system is sensitive to levels of methylation, as diets poor in folate and 
vitamin B12 required for AdoMet production cause demyelination (Kim et al., 2003). The myelin 
basic proteins (MBP) are known to contain a single sDMA (Brostoff and Eylar, 1971), but the 
physiological relevance of this modification and the PRMT that catalyze it in vivo remain unknown. 
It worthwhile to mention that the deimidation and the arginine methylation of MBP are increased in 
multiple sclerosis; this fact suggests the relevance of PTMs of arginine in this disease (Kim et al., 
2003). 
 
Spinal muscular atrophy 
The spinal muscular atrophy (SMA) is an autosomal recessive disease resulting from the loss of 
SMN1 gene function (Lefebvre et al., 1995). The SMN protein contains a Tudor domain that can 
bind both aDMA and sDMA motifs and interacts with some PRMT5 and CARM1 substrates 
(Cheng et al., 2007; Tadesse et al., 2008). The function of SMN is to act as a molecular chaperone 
for arginine-methylated proteins that participate in RNA metabolism. SMA patients show point 
mutations within the SMN Tudor domain (Cusco et al., 2004). 
 
 
1.3 PRMT6 
 
The Protein Arginine Methyltransferase 6 (PRMT6) exhibits type I PRMT activity (it is, in fact, 
capable of forming both ω–NG-momomethylarginine and asymmetric ω–NG, NG-dimethylarginine 
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derivatives), and can methylate itself. It was identified by homology to other PRMTs, has unique 
methylation properties, and can methylate arginines that reside within glycine-arginine-rich motifs 
(Frankel et al., 2002). However, PRMT6 tends to methylate arginines in non-glycine-arginine-rich 
motifs, as observed, for example, in HIV Tat protein (Boulanger et al., 2005) and DNA 
polymerase β (El-Andaloussi et al., 2006). Kinetic analyses have revealed that PRMT6 exhibits a 
distributive mechanism for multiple methylation of a single arginine residue (Lakowski and 
Frankel, 2008).  
The human protein PRMT6 has 375 amino acids residues, and is coded by the PRMT6 gene 
mapping in the human chromosome 1 (locus 1p13.3). The protein shows a highly conserved 
sequence, especially in methyltrasferase domains (Figure 3). 
 
hsPRMT6     MSQPKKRKLESG---GGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRN 77 
mmPRMT6     MSLSKKRKLESGDSGGAGAGGEGAEEENGGEQEAAPPRPRRTKSERDQLYYECYSDVSVHEEMIADQVRTEAYRLGILKN 80 
rnPRMT6     MSLSKKRKLESG-VG--GAGGEGAEEENGGEQEAAPPRPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRN 77 
ptPRMT6     MSQPKKRKLESG---GGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRN 77 
ppPRMT6     ----------------GGEGGEGTEEEDGAELEAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRN 74 
btPRMT6     MSQPKRRKLESG--GGGEGG-EGTEEEDGGELEVAVPRPRRTRRERDQLYYQCYSDVSVHEEMIADRVRTDAYRLGILRN 77 
cfPRMT6     MSQPKKRKLESG--GGGGGGGEGSEEEDGGAPEAAPPRPRRARRERDQLYYECYADISVHEEMIADRVRTDAYRLGILRN 78 
            :       :          * **:***:*.  *.*  ****:: *******:**:*:*********:***:*******:* 
 
hsPRMT6     WAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWM 157 
mmPRMT6     WAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRLNGLEDRVHVLPGPVETVELPERVDAIVSEWM 160 
rnPRMT6     WAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAQEVVRLNGLEDRVHILPGPVETVELPEQVDAIVSEWM 157 
ptPRMT6     WAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWM 157 
ppPRMT6     WAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWM 154 
btPRMT6     WAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASDIWQQAREVVRLNGLEDRVHVLPGPVETVELPEQVDAIVSEWM 157 
cfPRMT6     WAGLRGKTVLDVGAGTGILSLFCVQAGARRVYAVEASAIWQQARDVVRLNGLEDRVHVLPGPVETVELPEQVDAIVSEWM 158 
            **.*****************:**.************* *****::***:********:************:********* 
 
hsPRMT6     GYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIAPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIV 237 
mmPRMT6     GYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFVAPISDQMLEWRLGFWSQVKQHYGVDMSCMESFATRCLMGHSEIV 240 
rnPRMT6     GYGLLHESMLSSVLHARTKWLKEGGLLLPDSAELFVAPISDQMLEWRLGFWSQVKQHYGVDMSCMESFATRCLMGHSEIV 237 
ptPRMT6     GYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIAPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIV 237 
ppPRMT6     GYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIAPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIV 234 
btPRMT6     GCGLLHESMLSSVLHARTKWLKEGGLLLPASAELFVAPISDQMLELRLSFWSQMKQLYGVDMSCLESFATRCLMGHSEIV 237 
cfPRMT6     GYGLLHESMLRSVLHARARWLKEGGLLLPASAELFVAPVSDQMLELRLGFWSQVKQLYGVDMSCLESFATRCLMGHSEIV 238 
            * ******** ******::********** *****:**:****** **.****:** *******:*.************* 
 
hsPRMT6     VQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATH 317 
mmPRMT6     VQDLSGEDVLARPQRFAQLELARAGLEQELEAGVGGRFRCSCYGSAPLHGFAVWFQVTFPGGDSEKPLVLSTSPFHPATH 320 
rnPRMT6     VQGLSGEDVLARPQRFAQLELARAGLEQELEAGVGGRFRCSCYGSAPLHGFAIWFQVTFPGGDSEKPLVLSTSPFHPATH 317 
ptPRMT6     VQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATH 317 
ppPRMT6     VQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATH 314 
btPRMT6     VQGLSGEDVLARPQCFARLELARAGLEQELEAGVGGRFRFSCYGSAPMHGFAIWFQVTFPGGDSEKPVVLSTSPFHPVTH 317 
cfPRMT6     VQSLSGEDVLARPHCFARLELARSGLEQELEAGVGGRFRFSCYGSAPMHGFAVWFQVTFPGGDAEKPLVLSTSPFHPVTH 318 
            **.**********: **:***:*:***********************:****:*********::***:*********.** 
 
hsPRMT6     WKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED 375 
mmPRMT6     WKQALLYLNEPVPVEQDTDISGEITLLPSPDNPRRLRILLRYKVGDHEEKTKDFAMED 378 
rnPRMT6     WKQALLYLNEPVPVEQDTDISGEITLLPSRDNPRRLRVLLRYKVGDHEEKTKDFAMED 375 
ptPRMT6     WKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED 375 
ppPRMT6     WKQALLYLNEPVRVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED 362 
btPRMT6     WKQALLYLNEPVQVEQDTDVSGEITLLPSQDHHRHLRVLLRYKVGDQEEKTKDFAMED 375 
cfPRMT6     WKQALLYLNEPVPVEQDTDISGEITLLPSRDNHRLLRVLLRYKVGDQEEKTKDFAMED 376 
            ************ ******:**********:  * **:********:*********** 
 
 
Figure 3. Amino acids sequence alignment of PRMT6 of various organisms. It is evident the high sequence 
conservation between different species. Coloured amino acids belong to the methylatrasferase domains: blue is the 
domain I, red is the Post I, green is the II, and violet is the III. The THW loop is indicated in bold. Abbreviations: 
hs=Homo sapiens, mm=Mus musculus, rn=Rattus norvegicus, pt=Pan troglodytes, pp=Pongo pygmaeus, bt=Bos tauris, 
cf=Canis familiaris. 
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Comparing the amino acid sequence of all the PRMTs, PRMT6 seems to be the more similar to 
PRMT2. In fact it shows a 38% of sequence identity and a very high conservation of the catalytic 
core. The only difference with PRMT2 is that PRMT6 does not contain the homology domain SH3 
at the N-terminal.  
PRMT6 is predominantly nuclear and has automethylation activity (Frankel et al., 2002). Although 
its cellular role is not well understood, PRMT6 has been implicated in human immunodeficiency 
virus (HIV) pathogenesis, DNA repair, transcriptional regulation, and regulation of alternative 
splicing.  
To date, there are very few papers about PRMT6 substrates, but it is known that it is implicates in 
HIV pathogenesis by acting as a restriction factor for viral replication; in fact, it methylates some 
HIV proteins, as Tat (Boulanger et al., 2005), HIV-1 nucleocapsid protein (Invernizzi et al., 2007), 
and HIV-1 Rev protein (Invernizzi et al., 2006). Other proteins that are methylated by PRMT6 are 
the DNA polymerase β (El-Andaloussi et al., 2006), the architectural transcription factor HMGA1a 
(Miranda et al., 2005; Sgarra et al., 2006), the histone H3 at the R2 residue, and the histones 
H4/H2A at R3 residue (Hyllus et al., 2007).     
 
PRMT6 and regulation of gene expression 
A very recent article demonstrated that PRMT6 has a dual role in the regulation of the gene 
expression. In fact, using a luciferase reporter assay, Dowhan and co-workers demonstrated that 
PRMT6 could co-activate the progesterone, glucocorticoid and oestrogen receptors in a steroid 
hormone-dependent manner. Because PRMT1 and CARM1 have both been shown to be secondary 
co-activators that are recruited to steroid hormone receptors and nuclear receptors (SHRs/NRs) via 
the AD2 domains of p160/SRC proteins (Chen et al., 1999; Koh et al., 2001), they tested if also 
PRMT6 was able to bind SRC-1. Their results show that PRMT6 binds SRC-1 both in the N- and in 
the C-terminal region, where there are the bHLH/PAS and the AD2 domain respectively.  
Because transcriptional activity of PRMT6 was ligand-dependent, they concluded that PRMT6 was 
not a general transcription enhancer, but it acted as a co-activator for steroid hormone receptors 
(SHR). It is important to note that for the correct co-activation’s function, it is required the 
enzymatic activity of the enzyme (Harrison et al., 2010). Another study showed that 
thrombospondin-1 (TSP-1), a potent natural inhibitor of angiogenesis, was identified as a 
trancription repression target of PRMT6. In fact, using microarray analysis on U2OS osteosarcoma 
cells transfected with PRMT6 small interfering RNAs, it was demonstrated that PRMT6 associates 
with the TSP-1 promoter and regulates the balance of methylation of H3R2 and H3K4 (Michaud-
Levesque and Richard, 2009). 
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PRMT6 and alternative splicing 
Another process in which PRMT6 has been involved is the RNA processing. In fact it can regulate 
the alternative splicing of the vascular endothelial growth factor (VEGF) and Syk genes without 
requiring steroid hormone stimulation. Using the siRNA strategy to knockdown PRMT6, Dowhan 
and co-workers showed an increase in exon inclusion, and a decrease in exon skipping for both 
these genes in MCF-7 cells. In contrast to its effects on transcription, the regulation of the 
alternative splicing by PRMT6 is hormone-independent. It is worthwhile to mention that it is the 
second case in which a PRMT has a direct role in alternative splicing: CARM1 has been the first 
PRMT involved in this process (Cheng et al., 2007).             
 
PRMT6 – HIV-1 Tat protein   
Tat is a transactivator protein very important in Human Immunodeficiency Virus (HIV) type 1 
replication. In fact, it can dramatically increase gene transcription efficiency from the viral 5’ long 
terminal repeat (LTR) (Liang and Wainberg, 2002). Tat exerts this activity through binding to the 
Tat transactivation response region (TAR), a 57-nucleotide stem-loop RNA structure located at the 
5’ terminus of the nascent HIV RNA transcript. Moreover, Tat interacts with cyclin T1, that in turn 
recruits cyclin-dependent kinase 9 (CDK9) proximity of the C-terminal domain of RNA polymerase 
II. In this way, Tat stimulates the elongation efficiency of RNA polymerase II. In fact, CDK9 enacts 
the hyperphosphorylation of RNA polymerase II and accelerates RNA transcription (Wei et al., 
1998). This transactivation activity of Tat is regulated posttranslationally by the acetylation of 
lysine residues (K50) by histone acetyltransferase p300 (Kiernan et al., 1999; Ott et al., 1999). For 
example, Tat acetylation causes the dissociations of the Tat-cyclin T-CDK9 complex from TAR 
RNA and hence to transfer the latter protein complex to RNA polymerase II (Kaehlcke et al., 2003).  
Recently, it was shown that Tat is specifically associated with and methylated by PRMT6 
(Boulanger et al, 2005) in vitro and in vivo at residues R52 and R53 within the ARM motif, and this 
arginine methylation diminishes the transactivation capacity of Tat. In fact, methylated Tat can bind 
only weakly to TAR RNA or form Tat-TAR-cyclin T1 complexes, and this results in diminished 
transcriptional activation (Xie et al., 2007). In addition, another very recent paper demonstrated that 
PRMT6 methylation on Tat basic domain increases its half-life by 4.7 fold, and this stabilizing 
action allowed Tat to persist within the cell and the extracellular environment and thereby enable 
functions implicated in AIDS-related cancer, neurodegeneration, and T-cell death (Sivakumaran et 
al., 2009).  
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PRMT6 – HIV-1 nucleocapsid protein 
HIV-1 nucleocapsid (NC) is a small basic protein of 55 amino acids, synthesized as part of the Gag 
precursor polyprotein, which is cleaved into smaller components within the virion by the viral 
protease. Through the SL4 region of viral RNA, NC can bind the stem loop (SL) 1 to specifically 
package HIV-1 genomic RNA into virions (Sakaguchi et al., 1993; Amarasinghe et al., 2000). For 
these activities both of its two zinc finger motifs are required (Guo et al., 2000). NC is also involved 
in the annealing of the transfer RNALys3 to the primer binding site (PBS) of viral genomic RNA by 
means of two basic regions that flank the first zinc finger motif (Guo et al., 2000; Cen et al., 2000). 
It was shown that PRMT6 methylates in vitro and in vivo NC at R10 and R32, and this methylation 
results in decreased tRNALys3 annealing efficiency to the PBS and diminished initiation of reverse 
transcription (Invernizzi et al., 2007). 
 
PRMT6 – HIV-1 Rev protein  
Rev is a 116 amino acid protein, regulator of viral protein expression. It was found in the nucleolus, 
in the perinuclear zone and in the cytoplasm of infected cells (Pollard and Malim, 1998; Kalland et 
al., 1994); moreover, it can interact with the cis-acting Rev response element (RRE) located in the 
env gene (Meggio et al., 1996). The N-terminal portion of Rev harbors an arginine rich motif 
(ARM), a nuclear localization signal (NLS), and is responsible both for the binding to the RRE and 
for the REV nucleolar localization (Pollard and Malim, 1998; Fineberg et al., 2003). The ARM is 
also important because contains four major amino acids (R35, R39, N40, and R44) that participate 
in base-specific contacts with the high affinity bonding site of the RRE (Pollard and Malim, 1998; 
Battiste et al., 1996). In addition, the ARM is flanked by multimerization sites at which interaction 
between multiple Rev proteins is thought to take place during the binding of a single molecule of 
viral RNA (Pollard and Malim, 1998). Moreover, the Rev’s ARM is very similar to the one found 
in Tat protein, except for the fact that the ARM of Rev adopts an α-helical structure whereas that of 
Tat folds as a β-hairpin (Battiste et al., 1996).  
It was shown that PRMT6 binds and methylates Rev in the N-terminal of its ARM. One of the three 
arginine residues at positions 35, 38, and 39 is the methyl acceptor, but R38 being the most likely 
methyl-accepting residue. This methylation reduced RRE binding and diminished export of viral 
RNA to the cytoplasm (Invernizzi et al., 2006). A very important consequence of this PTM is that 
PRMT6 impairs HIV-1 Rev protein functions and can negatively regulate HIV-1 replication.  
 
PRMT6 – DNA Polymerase β  
In mammalian cells there are a lot of mechanisms to maintain their genome integrity (Hoeijmakers, 
2001). DNA base excision repair (BER) corrects damaged bases, apurinic sites, and single-strand 
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DNA breaks (Nilsen and Krokan, 2001). One small mammalian DNA polymerase constitutively 
expressed, the DNA polymerase β (Pol β) (Hubscher et al., 2002), is implicated in BER (Idriss et 
al., 2002; Sobol et al., 1996). The multifunctional, single polypeptide enzyme consists of 335 amino 
acids that build two functional domains, one with dRP-lyase activity and the other with 
nucleotidyltransferase function (Casas-Finet et al., 1991; Matsumoto and Kim, 1995; Prasad et al., 
1998), connected by a protease-sensitive hinge region (Idriss et al., 2002). Pol β has the ability to 
fill in short single-stranded DNA gaps up to 12 nucleotides (Singhal and Wilson, 1993) but lacks an 
associated exonuclease or proofreading activity. Moreover, it catalyzes the β elimination of 5’ dRP 
residues generated by the AP-endonuclease during BER (Matsumoto and Kim, 1995).  
Pol β directly interacts with and is methylated in R83 and R152 by PRMT6, and this methylation 
gives to Pol β a significantly higher DNA polymerase activity; this effect is due to the enhanced 
DNA binding and processivity of Pol β (El-Andaloussi et al., 2006). 
 
PRMT6 – Histone H3  
PTMs of histone N-termini, like methylation, acetylation, or phosphorylation, fulfill fundamental 
functions in the regulatory of gene expression and in the transcriptional memory during cell 
division (Strahal and Allis, 2000; Turner, 2002). These histone marks determine either an active or 
repressed chromatin state, depending on the nature and specific site of modifications (Jenuwein and 
Allis, 2001). For example, the tri-methylation of both H3K9 and H3K27 are repressive marks, 
whereas both the di- and the tri-methylation of H3K4 are characteristic of active promoter regions 
(Ito, 2007; Berger, 2007).  
PRMT6 methylates all four core histones in vitro, predominantly H3, H4, and H2A, but 
radiosequencing of the N-terminal histone tails revealed that R2 in histone H3 and R3 in histone H4 
and H2A are the major sites for PRMT6-mediated methylation. Some of the arginines targeted by 
PRMT6 in histones overlap with the substrate specificity of other PRMTs. For example, it was 
shown that R3 in H4 is modified both by PRMT1 and by PRMT5. Likewise, the R2 in H3 was 
suggested to be methylated by PRMT4, which predominantly methylates R17 in H3 (Ma et al., 
2001; Bauer et al., 2002). It is important to note that Bauer and colleagues showed that R2 in H3 is 
a unique site for asymmetric dimethylation by PRMT6 (Hyllus et al., 2007). In 2007, in fact, three 
different groups showed that the histone H3 was asymmetric dimethylated by PRMT6 at R2, and 
this modification counter-correlates with di- and tri-methylation of H3 lysine 4. The effect of this 
methylation caused an altered expression of some proteins. In fact, PRMT6 over-expression 
decreased HOXA5 expression, and had only a weakened effect on the repression of Cyclin D1. 
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While, on the contrary, PRMT6 knockdown increased the expression of HOXA5, and had a very 
strong repressive effect on Cyclin D1  (Iberg et al., 2008).  
Moreover, PRMT6 activity toward H3 peptide is reduced in the presence of H3K4 or H3K9 di-/tri-
methylation and slightly enhanced in the presence of H3K27 di-/tri-methylation (Hyllus et al., 2007; 
Guccione et al., 2007; Iberg et al., 2008). This mechanism revealed a negative cross-talk between 
arginine methylation and lysine methylation of histones. 
 
PRMT6 – HMGA1a 
The HMGA1a protein belongs to the High Mobility Group A (HMGA) family of architectural 
nuclear factors, whose activity is finely modulated by a variety of PTMs. One of these PTMs, is the 
arginine methylation: PRMT1, in fact, can methylate in vivo the R25 of HMGA1a (Zou et al., 
2007), PRMT1 and PRMT3 are able to weakly methylate HMGA2, and PRMT6 can methylates 
HMGA1a both in vitro and in vivo at R57 and R59 (Sgarra et al., 2006; Miranda et al., 2005). Mass 
spectrometry experiments indicate also that methylation in these two sites is mutually exclusive.     
These two residues are embedded in the second AT-hook, a region critical for both protein-DNA 
and protein-protein interactions and whose modification may cause profound alterations in the 
HMGA network. The motif recognized by PRMT6 in HMGA1a is the symmetrical sequence Pro-
Arg-Gly-Arg-Pro.  
In addition to R57 and R59, PRMT6 can in vitro methylate also R83 and R85 in the third AT-hook 
to a reduced level, and at very low level at the first AT-hook (Sgarra et al., 2006). The function of 
these methylations is not known yet, but arginine methylation in HMGA1a has been found to 
correlate with apoptosis and tumour progression (Edberg et al., 2004b; Sgarra et al., 2003). It is 
therefore possible that this PTM can play a direct role in modulating the HMGA1a function in these 
two processes. 
 
 
1.4 The family of HMGA proteins  
 
The family of HMGA consists of four members: HMGA1a, HMGA1b, HMGA1c, and HMGA2. 
Each protein contains specific functional domains called AT-hook, whereby they can bind 
preferentially regions AT-rich of B-DNA, and induce conformational changes to promote 
subsequent recruitment of other proteins to the site of binding (Huth et al., 1997). The acidic C- 
terminal tail of HMGA proteins, whose function is not yet known, seems to be important for the 
protein-protein interaction (Sgarra et al., 2004; Bianchi et al., 2005).   
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HMGA1a (106 amino acids, 11.5 kDa) and HMGA1b (95 amino acids, 10.5 kDa) are the variants 
of splicing more abundant and frequent in eukaryotic cells, and are identical in sequence with the 
exception of a deletion of a 11 amino acid region between the first and second AT-hook domain 
(Eckner and Birnstiel, 1989). Instead, HMGA1c (178 amino acids, 19.6 kDa) has in common with 
HMGA1a only the first 64 amino acid residues, because of the shift of the ORF caused by the 
alternative splicing (Nagpal et al., 1999). Even if the protein HMGA2 is coded by a different gene, 
it has a homology of 50% with the other principal members of the family. It has 108 amino acids, 
and a molecular weight of 12.0 kDa.  
This family is highly conserved evolutionary. As it is possible to see in Figure 4, comparing human 
and murine sequences, it is evident that there are only 3 different amino acids between hHMGA1 
and mHMGA1; while, for HMGA2 there are 4 different amino acids. The comparison between 
HMGA1 and HMGA2 sequences shows that the three AT-hooks are highly conserved.      
 
m HMGA1:  1 MSES GSKSSQPLASKQEKDGT ---EKRGRGRPRKQPP(VSPG 38
h HMGA1:  1 MSES SSKSSQPLASKQEKDGT ---EKRGRGRPRKQPP(VSPG 38
m HMGA2:  1 MSARGEGAGQPSTSAQGQPAAP VPQKRGRGRPRKQQQ ----- 37
h HMGA2:  1 MSARGEGAGQPSTSAQGQPAAP APQKRGRGRPRKQQQ ----- 37
m HMGA1: 39 TALVGSQ)KEPSEVPTPKRPRGRPKGSKNKGAAKT --RKVTT 77
h HMGA1: 39 TALVGSQ)KEPSEVPTPKRPRGRPKGSKNKGAAKT --RKTTT 77
m HMGA2: 38 --------- EPTCEPSPKRPRGRPKGSKNKSPSKAAQKKAE T 70
h HMGA2: 38 --------- EPTGEPSPKRPRGRPKGSKNKSPSKAAQKKAE A 70
m HMGA1: 78 APGRKPRGRPKK -----LEK----EEEEGI-SQESSEEEQ 107
h HMGA1: 78 TPGRKPRGRPKK -----LEK----EEEEGI-SQESSEEEQ 107
m HMGA2: 71 IGEKRPRGRPRKWPQQVVQKKPAQ E-TEETSSQESAEED 108
h HMGA2: 71 TGEKRPRGRPRKWPQQVVQKKPAQ EETEETSSQESAEED 109  
Figure 4. Comparison between HMGA1-HMGA2, human and murine. The amino acids sequences of HMGA1a/b 
and HMGA2 human (h) and murine (m) are reported. In red are highlighted the differences between the two forms. The 
acidic C-terminal domain is indicated in green. The grey boxes indicate the AT-hooks.    
 
 
All the HMGA proteins show some constant features: 
• A N-terminal domain with an unknown function and not so conserved between HMGA1 and 
HMGA2; 
• Three basic and highly conserved domains called AT-hooks to bind the minor groove of 
DNA in AT-rich regions (Reeves and Nissen, 1990); 
• An acidic C-terminal domain. Unlike other transcription factors, this domain has not 
transactivation activity; 
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• In HMGA2 proteins there is a spacer region of 12 amino acids located between the third 
AT-hook and the acidic tail. 
 
HMGA proteins are unfolded and intrinsically disordered. They have a relatively little α-helix or β-
sheet content and exhibits greater than 70% random coil (Slama-Schwok et al., 2000; Piekielko et 
al., 2001). Nevertheless, when specifically bound to other molecules, such as DNA or protein 
substrates, the HMGA proteins assume induced structural features. For example, when HMGA bind 
DNA, AT-hooks assume a planar, crescent-shaped configuration that specifically binds the minor 
groove of short stretches of AT-rich DNA (Huth et al., 1997; Reeves and Nissen 1990).  
Each HMGA protein has three similar, but independent, AT-hook peptides formed by 9 amino acids 
and with the consensus sequence Pro/Gly-Arg-Gly-Arg-Pro flanked on the other side by a number 
of positively charged lysine/arginine residues (Reeves, 2001).  
Comparing the structures of the three principal members of the HMGA family, it is evident that 
AT-hooks are differently spaced (Figure 5); probably this is responsible for the different binding 
specificity on the DNA.  
 
AT AT AT
AT AT AT
AT AT AT
HMGA1a
HMGA2
HMGA1b
1 106
1
1
95
108
 
 
Figure 5. Comparison between HMGA proteins. The AT-hook domains (in yellow) are located in a different way on 
the various HMGA proteins. In red are highlight the C-terminal acidic tails.        
 
 
It has been demonstrated that a single AT-hook could bind 5 bp of AT-rich DNA. The binding is 
strengthened if there is both a long stretch of DNA (10-16 bp) and more stretches of 5-8 bp spaced 
approximately 8 bp where more AT-hooks can bind the DNA (Cui et al., 2005). At the same time, 
HMGA can bind various DNA sequences, and for this reason it is possible to hypothesize the 
formation of a loop that allows to distant regions of DNA to contact each other (Bagga et al., 2000).  
The three AT-hooks have not equivalent functions; in fact, it was demonstrated that both the first 
and the second AT-hook are more involved in the binding of DNA in vivo (Harrer et al., 2004). The 
family of HMGA can determine structural changes of the DNA in the sequences that their bind 
causing loops, distortions, or folds, and modify its topologic conformation (Reeves, 2001).      
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Role of HMGA proteins 
 
The organization of HMGA proteins is similar to those of transcription factors; in fact they have 
both the functional domains that can bind the DNA and an acidic C-terminal domain. Even if this 
family of proteins have not trans-activation activities (Thanos and Maniatis, 1992), HMGA proteins 
can have a fundamental role in the regulation of the eukaryotic gene expression, through three 
mechanisms, summarized in Figure 6: 
1. Chromatin remodelling 
2. Formation of “enhanceosomes” 
3. Protein/protein interaction to regulate the activity of transcription factors 
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Figure 6. The more important functions of HMGA proteins. A. HMGA proteins de-repress the transcription through 
a competition with the Histone H1 at the level of specific chromatin sequences. B. HMGA can bind directly the DNA 
(1) inducing a conformational modification in its, to facilitate the binding of other transcription factors (2). C. HMGA 
can interact with transcriptional factors (1) with low affinity for the DNA, changing their conformation (2), and 
allowing their binding to the DNA with high affinity (Sgarra et al., 2004). 
 
1.Transcription regulation through chromatin remodelling 
HMGA proteins are interconnected with the chromatin. Studies of immunolocalization 
demonstrated that HMGA are integral components of the chromatin structure, and are mainly 
located at level of G/Q- and C- bands (Disney et al., 1989). These chromosomal regions are made 
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up mostly by SARs (Scaffold Attachment Regions) sequences that are very AT-rich, and have an 
important role in chromatin structuring. In the nucleus, the DNA is organized in ring structures of 
about 60 kb, in which are present SARs sequences to facilitate the attachment on the nuclear matrix. 
The SARs have both a structural role, and are important for various functions such as transcription 
or replication; in fact they regulate the accessibility to the chromatin (Jenuwein et al., 1997). 
Immunolocalization studies demonstrated that, at the SARs level, HMGA co-localize both with the 
Histone H1, and with the topoisomerase I, two proteins that compact the chromatin and are then 
associated with the repression of the gene transcription. In particular, it was demonstrated that 
HMGA proteins compete with Histone H1 for the binding to the DNA. In this way they act as anti-
repressors and activate the gene transcription (Martelli et al., 1998; Saitoh and Laemmli, 1994; 
Zhao et al., 1993). These data were also confirmed using the FRAP (Fluorescence Recovery After 
Photobleaching), a technique that allows to study the intracellular molecular dynamics in vivo. 
Using this approach, it was seen that HMGA1 proteins are able to weaken the binding of the 
Histone H1 to the chromatin; this effect was observed both in euchromatin and in eterochromatin 
(Catez et al., 2004). All together, these studies demonstrated that HMGA proteins could compete 
with the Histone H1 modulating the DNA compaction and, to achieve, the accessibility to the 
transcription factors. 
Besides to bind the chromatin, HMGA proteins can also bind histones H3, H2A, and H3 in vitro 
and in vivo (Reeves and Nissen, 1993). It was furthermore demonstrated that in the nucleosome 
structures, HMGA proteins could bind the DNA, changing its structure altering the helix periodicity 
and the rotational structure (Reeves and Wolffe, 1996). Based on these observations, it was 
hypothesized that one HMGA proteins in vivo function is to reposition the DNA at the nucleosomes 
level, and to participate at the nucleosomal disassembly to facilitate the binding of transcription 
factors to the DNA (Reeves and Wolffe, 1996).                        
 
2.Transcription regulation through formation of “enhanceosomes” 
HMGA proteins can regulate the gene expression in a gene-specific way, promoting the formation, 
on an enhancer sequence, of multi-molecular pre-transcriptional complexes called enhanceosomes. 
These complexes are needed for a specific and efficient transcriptional activation (John et al., 1995; 
John et al., 1996). The enhanceosome is an ordered complex consisting of transcription factors both 
general and gene-specific that interact among themselves and with regulative sequences of 
enhancer. The structures of enhancers and promoters are complex, and allow the assembly of a 
single enhanceosome to respond to different extra-cellular signals (Yie et al., 1999). The best 
characterized and studied enhanceosome, is that of the human virus-inducible IFN-β gene. The 
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sequence of the regulatory region of the IFN- β gene is composed by two negative regulation 
domains (NRDs) and three positive regulation domains (PRDs) that are adjacent and are called 
PRDIV, PRDIII-I, and PRDII (Falvo et al., 1995). At the structural level, the enhancer is flanked by 
two nucleosomes, and one of this is after the TATA-box (Munshi et al., 2001). The first step for the 
enhanceosome’s assembly is the binding of HMGA1 to the PRDII, PRDIV, and NRDI domains, 
that causes changes in the DNA, modifying the curve, and making it available to the action of the 
transcription factors (Yie et al., 1999). After this, there is the HMGA1-dependent recruitment of 
activators of the gene transcription for the IFN-β gene: NFkB (p50/p65), IRFs (Interferon 
Regulatory Factors), and ATF2/c-Jun (Borrmann et al., 2003). Moreover, it was demonstrated that 
HMGA proteins participate to the enhanceosome’s stabilization through a dense network of protein-
protein interactions. These multiple interactions involve also the binding between the same HMGA, 
between the factors ATF2/c-Jun and NF-kB, and, finally, between HMGA and factors mentioned 
above (Yie et al., 1999). During the enhanceosome’s assembling, activators create a new activation 
surface that recruits, and in the same time interacts with, the factors involved in the basal 
mechanism of transcription (Merika et al., 1998).   
Moreover, HMGA proteins participate in the in vivo regulation of various genes, through the direct 
interaction with several proteins, most of which are either transcription factors or co-activators 
(Reeves, 2001). To date, a lot of eukaryotic and viral genes are known to be regulated at 
transcriptional level by HMGA proteins (Reeves, 2001). Among these, most are positively 
regulated, such as the human insuline receptor (Brunetti et al., 2001) or the leptin gene (Melillo et 
al., 2001). In some cases, however, HMGA proteins can have a repressors action; for example, 
when either the HMGA binding causes alterations of the DNA structure that interfere with the 
binding of specific transcription factors to their specific sites, or the transcription factors recruited 
by HMGA proteins are transcription inhibitors. Using various techniques, several transcriptional 
factors and co-activators that specifically bind HMGA proteins were discovered. For a list and 
detailed informations about HMGA partners, visit the site 
http://www.bbcm.units.it/~manfiol/INDEX.HTM (Sgarra et al., 2010).  
 
Fore some partners of HMGA proteins, the interaction domain on HMGA was mapped (Figure 7). 
Some partners, such as NF-Y and ATF-2/c-Jun bind the N-terminal region of HMGA, but, on the 
contrary, IRF-1 binds the C-terminal tail. In the most of cases the main binding regions are the 
second AT-hook and the spacer region between the second and the third AT-hook. The second AT-
hook, as mentioned earlier, is both the domain mostly involved in the DNA binding, and the region 
more subjected to post-translational modifications. These data suggest that, similarly to the 
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enhanceosome, PTMs could modulate the binding of HMGA to their molecular partners and/or to 
the DNA, influencing their biological role.  
 
SESSSKSSQPLASKQEKDGTEKRGRGRPRKQPPVSPGTALVGSQKEPSEVPTPKRPRGRPKGSK NKGAAKTRKTTTTPGRKPRGRPKKLEKEEEEGISQESSEEEQ
I AT -hook II AT-hook III AT-hookSplicing
1 10 20 30 40 50 60 70 80 90 100 106
ATF-2/c-Jun: 1-53
IRF-1: 36-106
NF-Y: 1-36
SRF: 49-80
NF-!B: 53-73
p50: 52-66
Tst-1: 57 -67
Sp1: 54-74
C/EBP ": 54 -64
p53: 51-75        
Figure 7. Example of interaction domains on HMGA1a proteins. Most of interacting proteins bind the second AT-
hook. 
 
 
3.  Transcription regulation through protein/protein interactions 
HMGA proteins can in vivo regulate the transcription of various genes through different 
mechanisms, also independently by their DNA binding activities (Reeves and Beckerbauer, 2001). 
Protein/protein interactions can have both positive and negative effect to the gene regulation, and 
also HMGA proteins can contribute in these two ways.  
The transcription of the gene for the heavy chain of the immunoglobulin IgM is an example of 
HMGA regulation of gene expression (Lewis et al., 2001). For this case, it was demonstrated that 
the binding of the HMGA1a protein to the transcriptional factor PU.1 causes an increased binding 
affinity to the DNA of PU.1. After interacting with HMGA1a, there is a structural change of PU.1. 
In a similar way, HMGA proteins can in vivo activate the gene transcription for c-fos and SM22α 
through the interaction with the transcription factor SRF (Serum Response Factor) to strengthen the 
capacity of binding to the CarG box elements on their promoters (Chin et al., 1998).  
HMGA2 protein can activate the transcription of the human Cyclin A gene. It was demonstrated 
that the binding of HMGA2 on the repressor p120E4F causes a reduction of its DNA binding and an 
activation of the gene (Tessari et al., 2003).  
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1.5 Post-translational modifications of HMGA proteins 
 
Stability of a protein, its folding, conformation, distribution, localization, turnover, and interaction 
with DNA or other proteins is modulated by post-translational modifications (PTMs). 
The biological activities of the HMGA proteins are highly regulated by their post-translational 
modifications, including acetylation, methylation, phosphorylation, and ADP-ribosylation (Reeves, 
2001). These secondary biochemical modifications are dynamic and rapidly responsive to intra- and 
extracellular signalling events (Zhang and Wang, 2008).  
 
Phosphorylation 
PTMs of HMGA1 proteins have been extensively studied for more than 20 years. Phosphorylated 
HMGA1 proteins were detected in Ehrlich ascite cells (Lund et al., 1985) two years after their 
original identification in HeLa cells (Lund et al., 1983). Since then, HMGA1 proteins have been 
observed to be among the most highly phosphorylated proteins in the nucleus (Lund et al., 1985; 
Elton and Reeves, 1986). Further research revealed that HMGA1a and HMGA1b proteins could be 
phosphorylated by Casein kinase II (CK2) on three serines located in the C-terminal tail: S98, S101, 
and S102; the corresponding sites in HMGA1b are S87, S90, and S91 (numbers refer to the 
HMGA1a isoform, considering as amminoacid number 1 the N-terminal Serine constitutively 
acetylated), but the function of these phosphorylations has never been uncovered (Palvimo and 
Linnala-Kankkunen, 1989). The acidic C-terminal tails of HMGA1 proteins are constitutively 
phosphorylates in vivo but it is not directly involved in DNA binding. Conversely, several kinases 
modulate HMGA DNA-binding affinities through phosphorylation at specific sites. This is the case 
of p34cdc2, HIPK2, and PKC. 
The phosphorylation of p34cdc2 on the residues T52, and T77 of the HMGA1a protein reduce its 
affinity for the DNA (Nissen et al., 1991; Reeves et al., 1991). Recently, Zhang and Wang revealed 
that, other than these two sites, S35 could also be phosphorylated by p34cdc2. In addition, p34cdc2 can 
catalyze the phosphorylation of the corresponding T41, and T66 in HMGA1b (Zhang and Wang, 
2007). Moreover, Zhang and Wang showed that HIPK2 (homeodomain-interacting protein kinase-
2) could induce the phosphorylation at the same sites. The two kinases, however, exhibited different 
site preferences for the phosphorylation: the preference for HIPK2 phosphorylation followed the 
order of T77 > T52 > S35, whereas the order for p34cdc2 phosphorylation was T52 > T77 > S35. 
They found also that the HIPK2 phosphorylation reduced the binding affinity of HMGA1a to 
human germ line ε promoter, and this drop in binding affinity was lower than that caused by 
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p34cdc2; this is consistent with the notion that the second AT-hook of the HMGA1a is more 
important for DNA binding than the third AT-hook (Zhang and Wang, 2007). 
Another example of a phosphorylation as a mechanism for the regulation of HMGA1a function is 
the effect of PKC. The protein kinase PKC phosphorylates HMGA1a at T20, T43, and T63 and 
these events result in a reduction of DNA-binding affinity to the promoter regions of PKCγ and 
neurogranin/RC3 genes. HMGA1a could be additively phosphorylated by p34cdc2 and PKC, and the 
resulting doubly phosphorylated protein exhibited a >100-fold reduction in binding affinity (Xiao et 
al., 2000). 
Diana and coworker revealed that hyper-phosphorylation (at least five phosphate groups/ HMGA1a 
molecule) occurs at the early apoptotic stages in and is probably related to HMGA1a displacement 
from DNA and chromatin release from the nuclear scaffold. Instead, de-phosphorylation (one 
phosphate or no phosphate groups/HMGA1a molecule) accompanies the later formation of highly 
condensed chromatin in the apoptotic bodies  (Diana et al., 2001). In this work a direct link between 
apoptosis and the degree of phosphorylation in HMGA1a in leukemic cells is suggested. 
 
Acetylation 
In addition to phosphorylation, other PTMs, such as acetylation, have been implicated in 
modulating HMGA1 protein function. It has been shown that the N-termini of HMGA1a and 
HMGA1b proteins are constitutively acetylated in vivo in MCF-7 cells but no assignments of these 
modifications to specific lysine residues were made (Banks et al., 2000; Edberg et al., 2004). 
HMGA1a protein is also post-translationally acetylated in some lysine in vivo: K14 (Jiang and 
Wang, 2006), K64 and K70 (Munshi et al., 1998; Munshi et al, 2001), and K66 and K73 (Zhang et 
al., 2007).  
Five lysine residues in HMGA1a (K14, K64, K66, K70, and K73) could be acetylated by both p300 
and PCAF; these histone acetyltransferase exhibit different site preferences for the acetylation: the 
preference of p300 acetylation follows the order of K64 ~ K70 > K66 > K14 ~ K73, whereas the 
selectivity of PCAF acetylation follows the sequence of K70 ~ K73 > K64 ~ K66 > K14. The 
protein HMGA1b is acetylated in a very similar fashion as HMGA1a (Zhang et al., 2007). 
Moreover, Wang and co-workers demonstrated that C-terminal phosphorylation of HMGA1 
proteins did not affect the in vitro acetylation of the two proteins by either p300 or PCAF, and that 
the acetylation mediated by these two enzymes has distinct biological outcomes. The major 
acetylation site induced by CBP is K64, and this event destabilizes and disassemblies the 
enhanceosome, a higher-order nucleoprotein complex formed in response to virus infection; in 
1998, Thanos and co-workers demonstrated also that this acetylation of HMGA1 by CBP is 
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essential for turning off IFN-β gene expression. In addition, HMGA2 can also be acetylated by CBP 
and PCAF (Munshi et al., 1998). On the other end, the acetylation by PCAF at K70 facilitates 
enhanceosome assembly by increasing HMGA1’s affinity for activators. Therefore, the accurate 
execution of the IFN-β transcriptional switch depends on the ordered recruitment of PCAF and 
CBP, which acetylate HMGA1 at distinct lysine residues, inducing opposite effects on 
enhanceosome stability (Munshi et al., 2001).  
 
Methylation 
Methylation of HMGA1 proteins has been the least studied of the PTMs, and the importance of this 
type of modification is just beginning to be understood but seems to be strictly related to the 
execution of programmed cell death (Sgarra et al., 2003; Sgarra et al., 2003b). 
In this context, Sgarra et al., (Sgarra et al., 2003b) reported that the methylation occurs on R25 in 
the consensus GRG that belongs to the first DNA-binding AT-hook of the protein; the grade of this 
post transcriptional modification is definitively increased during apoptosis, and this increase could 
be related to heterochromatin and chromatin remodelling of apoptotic cells. In 2005 Zou and Wang 
(Zou and Wang, 2005) found that the R25 residue can be mono- and di-methylated in PC-3 human 
prostate cancer cells and both isoforms of dimethylation (symmetric and asymmetric) were 
detected. About this, it is important to note that neither monomethylation nor dimethylation was 
observed in HMGA1b protein isolated from PC-3 cells. Moreover they reported that the 
specificities of methylation among the three AT-hooks induced by PRMT1 and PRMT3 are 
different from those induced by PRMT6. PRMT1 and PRMT3, in fact, methylated HMGA1a 
preferentially at the first AT-hook at R25 and R23, to a lesser extent at the second AT-hook, and at 
minimum level at the third AT-hook. PRMT3 has less specific methyltransferase activity than 
PRMT1 and exhibits lower expression levels in nucleus than cytoplasm. Therefore, PRMT1 is more 
likely responsible for the methylation of R25 in vivo (Zou et al., 2007).  On the contrary, PRMT6 
methylated HMGA1a primarily in the second AT-hook at R57 and R59 both in vitro and in vivo 
(Sgarra et al., 2006; Miranda et al., 2005). And, in addition, PRMT6 can methylate R83 and R85 in 
the third AT-hook to a reduced level, and at very low level at the first AT-hook (Sgarra et al., 
2006). 
 
Poly(ADP) ribosylation  
In vivo experiments using Lewis lung carcinoma cells (LLC) showed that HMGA proteins could be 
poly(ADP) ribosylated. These experiments, in fact, demonstrated the ADP ribosylation of HMGA 
proteins was inducted after incubating the nuclei of LCC cells with CaCl2. It was proposed that this 
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modification occurs after DNA breaking because of treatment with Ca2+ ions, and this event starts 
the DNA repair mechanism in which the enzyme poli (ADP) ribose polymerase (PARP) is involved 
(Giancotti et al., 1996).   
 
PTMs of HMGA proteins in cancer cells 
Most of the study done on PTMs of HMGA1 proteins were based on proteins isolated from cultured 
human cell lines, but in this context, it is important to investigate fresh or fresh-frozen tissue 
without fixation so that the important aspects of human proteome and their modifications can be 
preserved (Ericsson et al., 2006).  
In 2004, Reeves and co-workers characterized the pattern of HMGA1a in vivo post-translational 
modifications found in a non-metastatic and two metastatic lines of MCF-7 human breast cancer 
cells of differing tumorigenic potential. Their work suggests that HMGA1a proteins, like the 
histones, exhibit a biochemical modification “code” that relates to cellular function. In fact, both 
increased levels of acetylation and a dimethylation of both lysine and arginine residues were found 
on HMGA1a proteins from metastatic cells over expressing HMGA1 proteins compared to proteins 
found in their non-metastatic precursor. It is worthwhile to note that also the types of modification 
present on K45 (unmodified, acetylation, or dimethylation) varied, depending on the metastatic 
potential of cells: it was modified by either mono- or di-methylation in metastatic cells, but was not 
modified in non metastatic cells (Edberg et al., 2004b). Another in vivo study about the PTMs of 
HMGA1a protein is Zou and Wang’s. In 2007, they detected novel PTMs of HMGA1a protein in 
cancerous human breast tissue: the monomethylation at K30 and K54 as well as 
monophosphorylation at S43 and S48. In these cancer tissue they also found that both the C-
terminal constitutive phosphorylation in HMGA1a and HMGA1b and the mono- and di-methylation 
of R25 in HMGA1a, which were identified previously in those protein isolated from human cancer 
cell lines, were present (Zou and Wang, 2007). 
In conclusion, other than the over-expression of HMGA1 proteins as potential cancer marker for 
both neoplastic transformation and metastatic progression, the types and sites of PTMs of these 
proteins may also serve as an important indicator for cancer cells (Zhang and Wang, 2007). 
Figure 8 summarizes all the PTMs of HMGA proteins identified to date. 
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Figure 8. Post translational modification of HMGA1 protein. The figure summarizes the PTMs of HMGA1 
identified. In red are reported methylations, in green acetylations, in blue phosphorylations, and in yellow formylations. 
 
 
 
1.6 The biologic role of HMGA proteins 
 
HMGA proteins have important roles both in physiologic and in pathologic processes. In 
physiologic processes, HMGA are essential for a correct embryonic development, in senescence, 
and in apoptotic processes. On the contrary, in pathologic processes, they participate at the genesis 
of cancers and/or metabolic disorders, like diabetes. 
 
1. Physiologic role 
HMGA and embryonic development  
The expression of HMGA genes is active both during embryogenesis and in rapid proliferating and 
undifferentiated cells, while it is very low (HMGA1) or absent (HMGA2) in normal adult tissues 
(Bustin and Reeves, 1996; Chiappetta et al., 1996). For this reason, it was hypothesized that this 
family of protein is involved in the control of cellular growth and differentiation. 
After exposure to factors stimulating metabolic activation and growth, HMGA genes can be rapidly 
induced in normal quiescent cells (Friedmann et al., 1993; Johnson et al., 1990; Ogram and Reeves, 
1995; Holth et al., 1997). HMGA genes below to the delayed-early responsive genes group that are 
activated by serum and others growth factors, during the G0-G1/S phases of the cellular cycle 
(Lanahan et al., 1992). 
 
HMGA and spermatogenesis 
In the spermatogenesis process HMGA proteins are very important. Expression studies in testes of 
wild-type mice, in fact, revealed that HMGA are expressed in nucleus of spermatogones, 
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spermatocytes, spermatids, and in Sertoli’s cells (Chieffi et al., 2002). Chimeric mice HMGA1a+/- 
have very little testes and are characterized both by deficiency of germinal cells (up to 100%) in 
seminiferous tubules and by vacuolated Sertoli’s cells (Liu et al., 2003). Moreover, it was also 
demonstrated a role for HMGA2 in the male gametogenesis; in fact the Nek2 phosphorylation on 
HMGA2 causes a detachment of the HMGA from the chromatin, while the unphosphorylated 
HMGA2 is bound to the DNA. The role of the kinase Nek2 is to maintain condensed the chromatin 
during mitotic divisions (Di Agostino et al., 2004).    
 
HMGA in senescence and apoptosis 
Cells in senescence can shape senescence-associated heterochromatin foci (SAHFs), 
heterochromatin structures preventing the activation of gene proliferation-associated by mitogenic 
transcription factors; in this way the expression of housekeeping genes remains unchanged. HMGA 
proteins accumulate in chromatin of senescence cells and are structural components of SAHFs, 
contributing to the repression of genes proliferation-associated. Moreover, in senescence, it was 
observed an increase of p16INK4a protein that blocks the D-CDK4 cyclin, whose function is to 
regulate positively the S phase of cellular cycle. p16INK4a’s action do not permit the phosphorylation 
of Rb, a negative regulator of E2F, by cyclin D. Recently, it was demonstrated that both HMGA1 
and HMGA2 cooperate with the tumour suppressor p16INK4a to promote SAHF’s formation and to 
repress gene proliferation-associated (Narita et al., 2006). 
On the contrary, about HMGA and apoptosis, it was observed that the transfection of HMGA1b 
gene in PC Cl3 thyroid cells causes apoptosis. In fact, over-expression of HMGA1b destabilizes 
their cellular cycle, and cells go in S-phase, and then lack the possibility to enter in M-phase 
(Fedele et al., 2001). Moreover, this apoptotic event is also characterized by the interaction of 
caspase-3 with HMGA1b. Caspase-3 recognizes both the acetylation of Lys 60 and the third AT-
hook (Fedele et al., 2001).          
Other studies conducted in different leukemic lines (HL-60, K562, NB4, and U937) demonstrated 
that apoptosis is characterized by an initial hyper-phosphorylation of HMGA1 proteins, and, later, 
by their massive de-phosphorylation. It was hypothesize that the hyper-phosphorylation event 
causes the detachment of HMGA from the DNA, which is now accessible to the action of 
endonucleases. On the contrary, the de-phosphorylation allows to HMGA to place itself on the 
DNA and participate to the chromatinic condensation of apoptotic cells (Diana et al., 2001). 
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2. Pathologic role 
HMGA and cancer 
Since their discovery, HMGA proteins have been strictly correlated with neoplastic transformation 
(Giancotti et al., 1985; Giancotti et al., 1987). HMGA protein levels are absent or very low in 
normal and differentiated adult tissue (Rogalla et al., 1996; Hirning-Folz et al., 1998), while their 
expression is high in embryonic and in undifferentiated cells (Bustin and Reeves, 1996; Chiappetta 
et al., 1996). Because the level of these proteins is highly correlated with the tumour aggressivity 
grade (Tallini and Dal Cin, 1999), they have been proposed as diagnosis markers both for the 
neoplastic transformation (Giancotti et al., 1989; Giancotti et al., 1991) and for metastatic potential 
of various tumours (Tamimi et al., 1993; Bussemakers et al., 1991). The expression of HMGA 
proteins is a characteristic independent by the cause generating the tumour, be it chemical, viral or 
caused by spontaneous mutations (Giancotti et al., 1989). 
The induction of the expression of exogenous HMGA1 protein in human breast epithelial cells 
demonstrated that these proteins cause the formation of primary tumour and metastasis in nude 
mice (Reeves et al., 2001). In the same way, hyper-expression both of HMGA1 and HMGA2 causes 
the neoplastic transformation of Rat1a and CB33 cell lines, conferring them the capacity to growth 
in soft agar and to cause tumours in nude mice (Wood et al., 2000). On the other hand, the 
inhibition of the synthesis of HMGA1 proteins in anaplastic cells of human thyroid inhibits the 
growth of neoplastic cells both in vitro and in vivo, but there is not interference with the growth of 
normal cells (Scala et al., 2000). The expression’s block of HMGA1 proteins in MCF7 cells with 
anti-sense constructs inhibits both the proliferation and the growth in soft agar (Reeves et al., 2001). 
HMGA1 proteins can also inhibit the nucleotide excision repair (NER) of the DNA, mechanism in 
which damaged nucleotides are substituted using information of the complementary nucleotides. 
With HMGA1-inducible MCF7 cells it was demonstrated that the HMGA1 protein expression 
increases the cellular sensitivity to UV ray, and this effect is due to the negative regulation of 
HMGA on genes involved in DNA repair. Among these, there are XPA and ERCC1 (Adair et al., 
2005). Accordingly to this, HMGA proteins can promote tumorigenesis, increasing the genomic 
instability. 
 
HMGA and diabetes 
The diabetes mellitus type 2 is a genetic disorder relatively heterogeneous that can be caused both 
by no response of peripheral tissue to the effect of insulin and by a reduced secretion of insulin 
from beta cells of pancreas (Kahn, 1994). The insulin action on target cells is mediated by a specific 
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receptor (INSR), located in the plasmatic membrane. This receptor seems to be a cause that origins 
this disorder; in fact either its elimination or the lack of its expression cause diabetes (Goldfine, 
1987). Studies on patients with diabetes mellitus type 2 showed that the decrease of expression of 
the receptor INSR is correlated with the diminished expression of the protein HMGA1a. In this 
context, the role of HMGA1 protein seems to be causal; in fact, in lymphoblast obtained by diabetic 
patients, after restoring HMGA1 level there is the re-expression of INSR, and cells have again the 
capacity to bind insulin. Similarly, interfering with HMGA1a expression in normal cells there is the 
inhibition of the insulin binding (Foti et al., 2005). A strong reduction of receptor INSr expression 
was seen also in knock-out mice for HMGA1 gene (HMGA1-/-) (Foti et al., 2005).      
The gene for insulin receptor has two AT-rich regions, called C2 and E3, necessary for a high in 
vivo transcriptional activity (Brunetti et al., 1993). HMGA proteins can bind these regions (Brunetti 
et al., 2001). In particular it was demonstrated that a multimolecular complex formed by HMGA1, 
Sp1, and C/EBPβ associate in these two sequences. In this context, the role of HMGA1 is very 
important because interacts with Sp1 and C/EBP1β and facilitates the binding on INSR promoter 
causing the activation of the gene transcription (Foti et al., 2003). 
 
HMGA and virus 
It was shown that HMGA proteins have a role both in the integration in the viral genome, and in the 
expression of viral genes in the host cells. An example of this duplex activity is reported in cells 
infected with HIV-1 virus, the Human immunodeficiency virus type 1. In fact, it was demonstrated 
that the pre-integration complex, used by the virus to be integrated in host genome, contains 
HMGA1a as an essential component. Moreover, the same protein cooperates with other factors at 
promoter level to modify the chromatin structure and permit the activation of the transcription of 
viral genes (Farnet and Bushman, 1997: Henderson et al., 2004). 
There are also other examples regarding other viruses and the involvement of HMGA proteins in 
the regulation of the viral gene’s expression involved in mechanisms of virus latency in host cells. It 
is important to note that HMGA action takes place through the binding to AT-rich sequences 
located in regulatory regions enhancer/promoter of viral genes. Thus, the transcription’s check is to 
realize in the same way of endogenous genes of host cells (Reeves and Beckerbauer, 2001).          
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2. AIMS OF THE STUDY 
 
 
Protein Arginine Methyltransferases (PRMTs) are recently discovered enzymes involved in various 
cellular processes, such as the nucleus/cytoplasm shuttling, transcription regulation, RNA 
processing, and DNA repair. In mammals nine PRMTs (PRMT1-9) are known. Among these, 
PRMT6 has a predominantly nuclear localization, and an automethylation activity. Very few 
information are known about both its substrates and its function. PRMT6 was shown to regulate 
both the gene expression, acting as a coactivator for steroid hormone receptors, and the alternative 
splicing of the vascular endothelial growth factor and Syk genes, without requiring steroid hormone 
stimulation. Known substrates of PRMT6 are three Human Immunodeficiency Virus proteins (Tat, 
Nucleocapsid, and Rev), DNA Polymerase β, Histone H3, and HMGA1a protein.    
HMGA nuclear architectural proteins are involved in chromatin organization and structure, playing 
a role in embryonic development and neoplastic transformation. These factors can modulate gene 
expression establishing interaction between the DNA and transcription factors located on enhancer 
and promoter regions, orchestrating the assembly of macromolecular complexes called 
“enhanceosomes”, such as the well-characterized IFN-β enhanceosome. In these complexes are 
often recruited enzymes that modify HMGA proteins, transcription factors and histones, resulting in 
regulating gene expression. Among these enzymes there are acetyltransferases, kinases and also 
arginine methyltransferases, in particular PRMT6. We decided to look for new partners and 
substrates of PRMT6, in order to understand the biological role of this enzyme. Results obtained 
could be useful to better characterize PRMT6, the context in which is involved, and to discover 
proteins that could modulate its activity. Moreover, the identification of common partners with 
HMGA proteins, could allow us to discover some new complexes in which PRMT6, HMGA, and 
the new common partners are involved.  
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3. MATERIALS AND METHODS 
 
 
3.1 Yeast two-hybrid protocols  
 
Yeast strain  
 
The yeast strain used is EGY48 (MATα, Trp1, Ura3, His3, LEU2::LEXAop6LEU2); it was 
ingegnerized to have mutations that make it auxotrophe for some nutrients. For some genome 
mutations, enzymes needed for the syntesis of Histidine, Tryptophan and Uracil are missing and the 
strain is auxotroph for these factors. It is also auxotroph for the Leucine. In fact in the regulatory 
region of the LEU2 gene (important for its synthesis) there is the sequence Lex Aop. It allows to 
LEU2 gene to function as a reporter; it is activated only in presence of a functional transcription 
factor with the LexA binding domain. This strain has also another reporter; in fact it was 
transformed with the plasmid pSH18-34 having LacZ gene under operator LexA control. This 
plasmid has the selection for the Uracil (URA3). These two reporters allow us to have a double 
control in the experiment. 
 
Plasmids 
 
Figure 1. Vectors used for the Yeast two-hybrid assay. pSH18-34 is the reporter used to transform the yeast strain. 
pEG202 is the vector used for the bait and pJG4-5 for the prey.  
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pGilda-PRMT6, pGilda-PRMT6Δ30, pEG202-PRMT6 and pEG202-PRMT6Δ30 vectors were yet 
available in the laboratory. The human fetal brain cDNA library, kindly provided by Prof. G. Del 
Sal (LNCIB, Trieste), was cloned in pJG4-5 vector between the sites Eco RI and Xho I.  
Using pEG202-PRMT6 as a template, five PRMT6 delection mutants were cloned in pEG202 
between Eco RI and Sal I sites. Primers used for PCR were the following:  
 
 
Oligo   Sequence 
 
PRMT6 wt up  5’- TTC GGG AAT TCA TGT CGC AGC CCA A - 3’ 
PRMT6 wt dw 5’- TTC AAA GTC GAC TCA GTC CTC CAT GGC -3’ 
PRMT6 184 dw  5’- TTC AAA GTC GAC GAG AAG ACC GCC C -3’  
PRMT6Δ86 up  5’- AAT ATT GAA TTC CTG GAC GTG GGC GCG -3’  
PRMT6 86 dw  5’- ATT CGT CGA CTC ATA CCG TCT TGC CTC G -3’ 
PRMT6Δ184 up 5’- AAA GAA TTC CTG CCG GCC TCC G -3’ 
 
Table 1. Primers used for PCR. These primers were used to clone with PCR various PRMT6 delection mutants in 
pEG202 vector.  
 
 
Yeast two-hybrid screening and interaction analyses 
 
pGilda-PRMT6, pGilda-PRMT6Δ30, pEG202-PRMT6 and pEG202-PRMT6Δ30 vectors were used 
to express fragments spanning the C-terminal or full-length PRMT6, linked to the C-terminus of 
LexA DNA-binding domain. Recombinant plasmids were transfected in Saccaromyces cerevisiae 
strain EGY48. After testing that it was not toxic for yeast, we decided to use pEG202-PRMT6 
construct, and we transformed yeast with a human fetal brain cDNA library expressing proteins in 
fusion with Gal4 activation domain (AD). Selection of transformants, β-galactosidase activity test, 
growth in absence of leucine test were performed by the conventional procedures (Bartel and 
Fields, 1987). 
 
Yeast transformation 
 
After over night growth in medium with appropriate selections, yeast are made competent using 500 
µl of LiAc/TE 1X (10 mM Tris/HCl pH 7.5, 1 mM EDTA, 0.1 M LiAc pH 7.5). The transformation 
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is carried out adding to 100 µl of yeast 1.5 µg of plasmid DNA, 50 µg of boiled-single strand 
salmon sperm (as carrier) and 600 µl of PEG 40% (10 mM Tris/HCl pH 7.5, 1 mM EDTA, 0.1 M 
LiAc pH 7.5, 40 g/l PEG3350). After heat shock (30 minutes at 30°C, 15 minutes at 42°C and 10 
minutes at room temperature) yeast are plated onto medium with the appropriate selections. Plates 
are incubated at 30°C for 2 days. 
 
High efficiency transformation  
 
The yeast strain is inoculated over night diluted to OD600=0.3 into 500 ml of liquid medium. Yeast 
have grown up to OD600=1.0. Yeast are then pelletted, washed 2 times with mQ water sterilized, 
and resuspended with 2 volumes of LiAc/TE 1.5X (15 mM Tris/HCl pH 7.5, 1.5 mM EDTA, 0.15 
M LiAc pH 7.5). With this protocol yeasts are made competent. 
For each transformation we used 5 µg of library, 180 µg of boiled-single strand salmon sperm 
(these are the optimal conditions screened in this job), 200 µl of competent yeast, and 1200 µl of 
PEG40%. Heat shock is realized incubating the transformation mix at 30°C for 30 minutes and then 
at 42°C for 15 minutes shaking. At the end, yeast transformated are plated onto medium with the 
appropriate selections. Plates are incubated at 30°C for 2 days. 
 
Western blot  
 
2 ml of medium are incubated with each clone to be analyzed and are make grow at 30°C over night 
shaking. Yeast cells are then pelletted and resuspended with 100 µl of running buffer (62.5 mM 
Tris/HCl pH 6.8, 2% SDS, 10% glycerol). To this tube 50 µl of glass bead are added. Cells are 
shaking for 10 minutes in vortex for the mechanic lyses, and then are boiled at 94°C for 5 minutes. 
After centrifugation, 15 µl of supernatant were loaded in a mini-gel SDS and, after the 
electrophoretic running, blotted into a nitrocellulose membrane for the recognition with antibody.  
For the western blot analysis, the antibodies α-LexA (mouse, Santa Cruz SC-7544, 1:1000) and α -
mouse perox (1:5000) were used. 
 
Minipreparation of DNA 
 
A single yeast clone is growth in 2 ml of selective medium for the plasmid of interest for 12 hours 
at 30°C. After centrifugation, cells are resuspended in 200 µl of Smash Grab solution (2% Triton X-
100, 1% SDS, 100 mM NaCl, 10 mM Tris/HCl pH 8, 1mM EDTA) and lysated using 50 µl of glass 
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beads following shaking with vortex for 5 minutes. There follow a phenol/clorophorm extraction 
1:1 and a DNA precipitation with NH4COOH (2.5 M final concentration) and 2 volumes of EtOH 
for 30 minutes at -80°C. After these, there is a washing with 70% Ethanol and, after centrifugation, 
the DNA is resuspended with 100 µl of mQ. 
 
 
3.2 GST Pull-Down to validate Y2H results  
 
Plasmids 
 
cDNA coding for PRMT6, HMGA1b and HMGA2 were already cloned in fusion with the GST-Tag 
in pGEX 6p-1 (PRMT6) and in pGEX 4T-2 vectors (HMGA proteins). Putative partners were 
cloned between the Eco RI and Xho I sites of the vectors pcDNA3HA and pGEX4T-1. For some 
proteins it was not possible a direct cloning, and they were generated either by a two-steps cloning 
or by PCR using pJG 4-5 vector as template. 
Primers used for PCR were the following:  
 
 
Oligo   Sequence 
 
PRDX4 up  5’- AAT TAA GGA TCC GCC ACC GAA GGC TGC- 3’ 
PRDX4 dw   5’- GGT GGC TCG AGG GTA ATG AAA CCG TGA AC -3’  
 
POMP up   5’- AAT TAC GGA TCC AGA GAG GCT GTT CGC AGA -3’  
POMP dw   5’- GGG TGC TCG AGC AGG TGT CAG TAC TTT AA -3’ 
 
HPRT1 up   5’- GGC GGG GAT CCG GGG CTA TAA ATT CTT -3’ 
HPRT1 dw   5’- GGC GGG TCT AGA ATA GTG CTG TGG GTT AA -3’  
 
PKX1 up  5’- AAA TAA GGA TCC CCC CGG ACT GGG CG -3’ 
PKX1 dw   5’- AAG GTC TCG AGT CAG AAT CTG GCA GAT GAC -3’  
 
Table 2. Primers used for PCR. These primers were used to clone with PCR some partners in pGEX4T-1 vector. 
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Proteins GRSF, MTF2, SnRNP B, CDK5, and Septin 7 were cloned in two steps between the 
enzymes Bam HI-Xho I (GRSF), Bam HI-Xho I (MTF2), Eco RI-Xba I (SnRNP B), Bam HI-Xba I 
(CDK5), and Bam HI- Xba I (Septin 7). 
 
Proteins purification  
 
GST, GST-PRMT6, GST-HMGA1b, and GST-HMGA2 were over-expressed in E. coli Ros2DE3 
by induction with a final concentration of 0.5 mM isopropyl-β-D-thiogalactopyranoside for 2 hours 
at 37°C. Bacteria cells were pelletted by centrifugation and lysed in lyses buffer (1%NP-40, 5mM 
EDTA, 1mM PMSF (phenyl-methyl-sulphonyl-fluoride) in 1X PBS) completed with 0.4 mg/ml of 
Lisozyme and 200 µl of PIC (Protease Inhibitor Cocktail, Sigma) for each ml of pellet. The 
supernatant were incubated for almost 2 hours with the resin Glutathion Sepharose 4B (Amersham 
Bioscences) for the binding. After this, there were 3 washing with lyses buffer. At the end the resin 
was resuspended in lyses buffer. 
 
In vitro GST pull-down assay 
 
The GST pull-down assay was performed incubating 5 µg of recombinant protein (GST, GST-
PRMT6, GST-HMGA1b, and GST-HMGA2) bound to the resin with 10 µl of each putative partner 
translated in vitro by using a commercial in vitro transcription-translation kit (TNT; Promega) with 
35S-Methionine (PerkinElmer), using 200 µl of Binding buffer (25 mM HEPES pH 7.9, 50 mM 
NaCl, 1 mM DTT, 0.01% NP-40). After these, proteins bound to the resin were washed 2 times 
using Binding buffer with 0.25% of BSA, and 2 times with the Binding buffer without BSA. 
Proteins were then resolved by SDS-PAGE (15%) and visualized by autoradiography. 
For this experiment partners were cloned in pcDNA3HA vector between Eco RI and Xho I sites. 
 
 
3.3 Confirm the interaction in vivo 
 
Plasmids 
 
PRMT6 was subcloned from pGex6p1 hPRMT6 in the expression vector pcDNA3MBP vector 
(kindly provided by Dr. L. Collavin) between Bam HI and Xho I sites. This is a pcDNA3 vector 
(Invitrogen) in which the Maltose Binding Protein (MBP) domain was cloned between Hind III and 
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Xho I sites upstream of the polylinker to permit the expression of the protein of interest in fusion 
with it. The peculiarity of this tag is its affinity for the Amylose resin useful for the subsequent 
purification. 
 
Cell lines  
 
Hek293T cells were grown at 37°C in a humidified 5% CO2 incubator in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 
U/ml) and streptomycin (100 µg/ml). Hek293T is a human embryonic kidney cell line. 
 
Co-Affinity purifications 
 
Transfections were performed by the standard calcium phosphate procedure precipitation method. 
Hek293T cells were plated at the density of 3.5 x 105 cells per 35-mm-diameter culture dish and 
processed 32 hours after removal of the precipitates. Cells are then washed with phosphate-buffered 
saline and then harvested in 400 µl of ice-cold lysis buffer (50 mM Tris/HCl pH8, 0.1% NP-40, 150 
mM NaCl, 5% Glycerol, 500X Na3VO4, 5 mM NaF, 2 mM DTT (dithiothreitol), 5 mM EDTA 
supplemented with 1mM PMSF (phenyl-methyl-sulphonyl-fluoride) PIC (Protease Inhibitor 
Cocktail, Sigma). Lysis was performed at 4°C for 30 minutes. The lysates were then clarified by 
centrifugation and incubated with 10 µl of Amylose Resin (New Englan BioLabs) for 2 hours at 
4°C. Samples were then washed three times in 1 ml of ice-cold-lysis buffer and the bound proteins 
were solubilized by addition of 15 µl of SDS-containing sample buffer. Western Blot analysis was 
performed by standard procedures with anti-MBP (rabbit, 1:2000) and anti-HA (mouse, 1:5000) 
primary antibody. Bound primary antibodies were visualized by enhanced chemiluminescence. 
 
 
3.4 Identification of PRMT6 new substrates  
 
Plasmids 
 
For in vitro methylation experiments, all partners previously cloned in pcDNA3HA were subcloned 
in pGEX 4T-1 vector between Eco RI and Xho I sites. 
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In vitro methylation assay 
 
GST-PRMT6 was expressed and purified as describe above. After the binding, the resin was 
washed 3 times with ice-cold PBS and the protein GST-PRMT6 was eluted with the Eluition buffer 
(15 mM Glutathione reduced in 50 mM Tris pH 8 and 120 mM NaCl). The protein eluted was then 
checked by SDS-PAGE (10%) for the correct production and quantity normalization with Blu 
Coomassie Staining.  
1 µg of each putative partner was incubated with 1 µg of recombinant protein GST-PRMT6 in 
presence of S-adenosyl-L-(methyl-3H)methionine.radiolabeling (PerkinElmer). The methylation 
was conducted for 1 hour at 30°C and then blocked with the heat inactivation of the enzyme (5 
minutes at 94°C). Proteins were then separated by SDS-PAGE (15%) and, after blue Comassie 
staining, gels were soaked in NAMP100 Amplify (Amersham Biosciences), air dried and expose to 
films at –80°C for few days. 
For the in vitro methylation in presence of HMGA proteins 200 ng of each partners were used, and 
the in vitro methylation assay were conducted for 16 hours. The HMGA recombinant proteins used 
were: HMGA1a wild-type, HMGA1a52, and HMGA1aR57,59A (Sgarra et al., 2006).   
 
 
3.5 MIF’s functional assay  
 
Plasmids 
 
MIF was cloned by PCR, using the vector pBabe human MIF as a template, both in 
pcDNA5/FRT/to GFP vector between Bam HI and Xho I sites, and in pCS3 MYC vector between 
Bgl II – Xho I sites. Primers used for PCR were: 
 
  
Oligo   Sequence 
 
MIF up  5’- AAT TTA GGA TCC ATG CCG ATG TTC AT- 3’ 
MIF dw   5’- TAT TTG CTC GAG TTA GGC GAA GGT GG-3’  
 
Table 3. Primers used for PCR. These primers were used to clone with PCR the cDNA of MIF both in 
pcDNA5/FRT/to GFP, and in pCS3 MYC vector.  
 
Materials and methods 
43 
Cell lines 
 
Hek293T cells were grown at 37°C in a humidified 5% CO2 incubator in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 
U/ml) and streptomycin (100 µg/ml). Hek293T is a human embryonic kidney cell line. 
 
 
Transfection and luciferase assay  
 
Transfections were performed by the standard calcium phosphate procedure. Hek293T cells were 
plated at the density of 3.5 x 105 cells per 35-mm-diameter culture dish and processed 32 hours 
after removal of the precipitates. For luciferase assay, cells were transfected with 1 µg of the 
reporter construct, the indicated amounts of the expression vectors, and 0.1 µg of pRL-CMV 
Renilla luciferase expression vector (Promega) to normalize for transfection efficiencies. The assay 
was performed with the dual-luciferease reporter assay system (Promega) according to the 
manufacturer’s instructions.     
 
 
 
Results 
44 
 
4. RESULTS 
 
 
4.1 Yeast two-hybrid screening 
 
The yeast Two-Hybrid System (Y2H) is a technique used to discover protein-protein interactions in 
vivo by testing the binding between a protein called “bait” and a library of cDNA called “pray”. 
The activation of downstream reporter gene by the binding of a transcription factor onto an 
upstream activating sequence (UAS) allows the detection of the interaction. For the purposes of the 
Y2H, the transcription factor is split into two separate regions called binding domain (BD) and 
activating domain (AD). The BD domain is responsible for binding to the UAS and the AD is 
responsible for activation of transcription. 
The key of Y2H is that in most eukaryotic transcription factors the activating and binding domain 
are modular and can function in close proximity to each other without direct binding. This means 
that even though the transcription factor is split into two fragments, it can still activate transcription 
when the two fragments are indirectly connected. 
For this screening, the bait PRMT6 was cloned in fusion with the DNA binding domain of LexA, 
and the pray, in our case a human fetal brain cDNA library, was cloned in fusion with the activation 
domain of B42. If the two proteins interact each other, the transcription factor will be reconstituted, 
and it will allow both the transcription of two reporter genes: LacZ and Leu2. This technique is very 
useful to look for new molecular partners, in fact it allows the screening of a library in a cellular 
environment. It is also possible to choose interacting proteins for their strength of binding. 
The Figure 1 summarizes the mains steps of the yeast two-hybrid screening. 
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Figure 1. Yeast two-hybrid flowchart. Principal steps of the Y2H screening with a cDNA library are shown.  
 
 
In order to use PRMT6 as bait: 
• It must be not toxic for yeast 
• It must be without transactivating capability  
 
The first step was then to characterize the bait in order to avoid a possible toxicity.    
1. PRMT6 full length cDNA was cloned in the pEG202 vector fused with the DNA 
Binding Domain LexA and under the control of the constitutive promoter ADH1 
(alcohol dehydrogenase 1). 
2. PRMT6 full length cDNA was cloned in pGILDA vector fused with LexA operator 
but under Gal1 inducible promoter control. This strategy allows us to express the 
bait only if there is galactose in the medium and not if there is glucose.  
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3. The deletion mutant PRMT6Δ30, missing of the N-terminal region, was cloned in 
the vector pEG202 in fusion with the LexA operator under the control of ADH1 
constitutive promoter. In this mutant the methyltransferase domain is present but is 
missing a region of the protein in order to reduce possible problems of toxicity. 
 
The three plasmids were transformed in EGY48/pSH18-34 yeast. Western blot were performed to 
control the expression of the bait, with 4 clones for each bait, using for the detection a monoclonal 
antibody for the LexA protein. 
As it is possible to see in Figure 2, all clones were positive for the expression of the bait LexA-
PRMT6. Antibody recognized a fusion protein of about 70 kDa, a molecular weight that was 
expected, since LexA is 25 kDA and PRMT6 is 43 kDa.  
The bait is cloned under the control of a constitutive promoter and it is expressed both in medium 
with glucose (lanes 1, 3, 5, and 7) and in medium with galactose/raffinose (lanes 2, 4, 6, and 8). 
The different expression is due to the different growth of yeast into two mediums. 
 
 
 
Figure 2. Control of the bait expression with Western Blot. SDS-PAGE of cellular lysates obtained from cells of 4 
different clones of the yeast strain EGY48/pSH18-34/pEG202-PRMT6. For the western blot analysis, the antibody anti-
LexA was used. All clones express the fusion proteins LexA-PRMT6 (lanes 1-8). 
 
 
The same control was performed for clones EGY48/pSH18-34/pEG202-PRMT6Δ30: they express 
the bait both in presence of glucose and in presence of galactose/raffinose (Figure 3). 
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Figure 3. Control of the bait expression with Western Blot. SDS-PAGE of cellular lysates obtained from cells of 4 
different clones of the yeast strain EGY48/pSH18-34/pEG202-PRMT6 Δ30. For the western blot analysis, the antibody 
anti-LexA was used. All clones express the fusion proteins LexA-PRMT6 Δ30 (lanes 1-8). 
 
The same experiment was performed also for the expression of pGILDA-PRMT6 to valuate the 
effective inducibility of the system (Figure 4). The expression of the fusion protein LexA-PRMT6 
was not detected in medium with glucose (lanes 1, 3, 5, and 7), while it was present in medium with 
galactose/raffinose (lanes 2, 4, 6, and 8). All 4 clones were positive for the expression of the bait. 
 
 
 
Figure 4. Control of the bait expression with Western Blot. SDS-PAGE of cellular lysates obtained from cells of 4 
different clones of the yeast strain EGY48/pSH18-34/pGILDA-PRMT6. For the western blot analysis, the antibody 
anti-LexA was used. The expression of the bait is inducible with galactose (lanes 2, 4, 6, and 8), but not with glucose in 
the medium (lanes 1, 3, 5, and 7). 
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These experiments allowed us to valuate the possible toxicity of the bait; PRMT6 was not toxic for 
yeast. These data suggest that all the three systems are available to use in the two-hybrid screening. 
For the subsequent experiments we used the constitutively expressed full length PRMT6 protein. 
We then tested the bait for its transactivating activity. The yeast transformed with pEG202-PRMT6 
should not activate the transcription of the reporter genes LEU2 and LacZ. For this purpose, a clone 
of yeast EGY48/pSH18-34/pEG202-PRMT6 was analyzed both for its ability to grow without 
leucine, and for the development of blue colour in presence of X-Gal. After 2 days of incubation at 
30°C it was observed no blue colour development and no growth, thus demonstrating the absence of 
transactivating ability of the bait (data not shown). 
 
 
Test the bait with a positive control 
 
To ascertain the effective possibility to use PRMT6 in a two-hybrid assay, it was decided to test the 
bait with a partner already known in literature.    
PRMT6 is a Protein Arginine Methyltransferase with auto-methylation activity (Frankel et al., 
2002). But in order to do this, PRMT6 has to form homodimers; so this allows us to use PRMT6 
itself as a positive control.  
The ORF of PRMT6 was previously cloned in fusion with the bacterial transactivator domain B42 
in pJG4-5 vector. As a negative control we used the vector pJG4-5 BRD7, coding for a nuclear 
transcription factor that should not interact with PRMT6. 
Three different yeast clones of EGY48/pSH18-34/pEG202-PRMT6/pJG4-5-PRMT6 and of 
EGY48/pSH18-34/pEG202-PRMT6/pJG4-5-BRD7 were screened for their growth in medium in 
the absence of leucine and for blue staining in the presence of X-Gal. 
As expected, PRMT6/BRD7 did not activate reporter genes, while the PRMT6/PRMT6 interaction 
did, and it was very strong. 
To control for the correct expression of both the bait and the prey, we performed a Western Blot 
analyses.    
We used antibody that recognizes LexA to identify the bait, and the antibody anti-HA to verify the 
presence of the HA epitope of the pray protein (B42-HA-PRMT6). As it is possible to see in Figure 
5, the bait is constitutively expressed both in medium with glucose and in medium with 
galactose/raffinose (lanes 1-6), while the expression of the first prey was detected only in the 
presence of galactose/raffinose as expected since the promoter is inducible. 
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Figure 5. Western Blot assay to confirm the interaction bait/prey. The bait LexA-PRMT6 is constitutively 
expressed in all clones used for the experiment (lanes 1-6), while the pray B42-HA-PRMT6 is expressed in an inducible 
way with galactose/raffinose (lane 8, 10, and 12) in all clones screened. For the western blot analysis, the antibody anti-
LexA for the bait and anti-HA for the prey were used. 
 
 
Transformation of the library    
 
For the two-hybrid screening, we used a human fetal brain cDNA library, kindly provided by Prof. 
G. Del Sal. 
For the screening in Y2H, it is very important to have a high representation of the library; only in 
this case it is possible to screen the highest number of partners. For this reason, we paid much 
attention to optimize the transformation efficiency of the library. In order to do this, we tested 
different amounts of DNA carrier in the transformation. The best conditions allowed us to obtain 
about 28.500 clones/µg of library.  
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Primary and secondary screening  
 
After the transformation of the library, we selected only clones that were able to grow without 
leucine and showed blue staining in the presence of X-Gal in the medium. 
To confirm the interaction of PRMT6 with putative partners resulted by the primary screening, in a 
secondary screening, the plasmid DNA of interactors was extracted and used to transform in B290 
cells with electrophoration. For each transformation, we chose three different colonies, and the 
DNA was checked for the presence of the insert with Eco RI-Xho I restriction. 
To avoid false positive, for the secondary screening we used only plasmids for which at least 2 out 
of 3 had the same restriction pattern.  
Positive plasmids were transformed again in yeast EGY48/pSH18-34/pEG202-PRMT6, and the 
clones obtained were screened for the expression of the reporters. 
At the end, 179 clones were confirmed and identified after DNA sequencing. Among these, 36 
resulted to be unique, and can be divided in 4 main families: 
1. Transcription factors (4 proteins) 
2. RNP (ribonucleoproteins) or protein involved in RNA processing (8 proteins) 
3. Proteins involved in the proteasome degradation (4 proteins) 
4. Others (20 proteins) 
Results are summarized in Table 1.   
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Protein interacting with PRMT6  Localization Function  Found 
clones 
Accession 
number 
TRANSCRIPTION     
Mediator of RNA polymerase II 
transcription subunit (Med28, 
Magicin) 
N, C, M, 
PM  
Regulate transcription of nearly all RNA 
polymerase II-dependent genes 
71 Q9H204 
Metal-response element-binding 
transcription factor 2 (MTF2) 
N Binds to the metal-regulating-element 
(MRE) of metallothionein-1A gene promoter 
1 Q9Y483 
CDK5 regulatory subunit-
associated protein 3 
(CDK5RAP3) 
U Potential regulator of CDK5 activity. May be 
involved in cell proliferation 
1 Q96JB5 
Nucleoside diphosphate kinase 
A (nm23-H1) 
C, N Synthesis of nucleoside triphosphates other 
than ATP 
2 P15531 
RNA     
Proliferation-associated protein 
2G4 (ErbB3-binding protein 1, 
EBP1) 
C, N, n May play a role in a ERBB3-regulated signal 
transduction pathway. Seems be involved in 
growth regulation 
3 Q9UQ80 
RNA-binding protein NOB1 N May play a role in Mrna degradation 2 Q9ULX3 
U3 small nucleolar RNA-
associated protein 6 homolog 
(UTP6) 
N, n Nucleolar processing of pre-18S ribosomal 
RNA 
1 Q9NYH9 
Heterogeneous nuclear 
ribonucleoprotein Q (hnRNP Q) 
C, m, N mRNA processing mechanisms 1 O60506 
G-rich sequence factor 1, 
GRSF-1 
C Binds RNAs containing the 14 base G-rich 
element 
2 Q12849 
Cell division protein kinase 9 
(CDK9) 
N Member of the cyclin-dependent kinase pair 
(CDK9/cyclin-T) complex 
1 P50750 
Small nuclear 
ribonucleoprotein-associated 
proteins B and B' (snRNP-B) 
N May have a functional role in the pre-mRNA 
splicing or in snRNP structure 
1 P14678 
Pre-mRNA-processing factor 39 
(PRPF39) 
N Involved in pre-mRNA splicing 1 Q86UA1 
PROTEASOME     
26S proteasome non-ATPase 
regulatory subunit 11 
N, c Involved in the ATP-dependent degradation 
of ubiquitinated proteins 
10 O00231 
Proteasome activator complex 
subunit 1 (PA28alpha)  
N, c Implicated in immunoproteasome assembly 
and required for efficient antigen processing 
2 Q06323 
Proteasome subunit beta type-4 
[Precursor] 
C, N Subunit of the proteasome, multicatalytic 
proteinase complex  
1 P28070 
Proteasome maturation protein 
(POMP) 
C, c, N Chaperone essential for the assembly of 
standard proteasomes and 
immunoproteasomes.  
1 Q9Y244 
OTHERS     
Huntingtin-interacting protein K 
(HYPK) 
 May interact with the N-terminus of HD 17 Q9NX55 
Peroxiredoxin-4 (PRDX4) C Probably involved in redox regulation of the 
cell. Regulates the activation of NF-kappa-B 
in the cytosol  
5 Q13162 
Serum amyloid A-like 1 
(SAAL1) 
N Apolipoprotein positive acute phase reactant 
protein 
5 Q96ER3 
Ferritin L-chain [Fragment] 
(FtL) 
Mit Storage of iron in a soluble and nontoxic 
state 
1 O00563 
Heat shock protein beta-1 
(HSPB1) 
C, N Involved in stress resistance and actin 
organization 
1 Q96EI7 
Macrophage migration 
inhibitory factor (MIF) 
C, N Role for the mediator in regulating the 
function of macrophage in host defense. Also 
acts as a phenylpyruvate tautomerase 
8 P14174 
Histidine triad nucleotide-
binding protein 1 (Hint1) 
C, N Hydrolyzes adenosine 
5'monophosphoramidate substrates  
6 P49773 
Hypoxanthine-guanine C Defects in HPRT1 are the cause of Lesch- 9 P00492 
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phosphoribosyltransferase 
(HPRT1) 
Nyhan syndrome (LNS) 
39S ribosomal protein L38 
(L38mt) 
Mit Ribosomal protein 2 Q96Q66 
L-lactate dehydrogenase B 
chain (LDH-B) 
C Defects in LDHB are a cause of hereditary 
LDHB deficiency 
2 P07195 
Fumarate hydratase, 
mitochondrial [Precursor], 
Fumarase 
Mit, C Also acts as a tumor suppressor 1 P07954 
6-pyruvoyl tetrahydrobiopterin 
synthase, PTP synthase (PTPS) 
Mit Involved in the biosynthesis of 
tetrahydrobiopterin 
4 Q03393 
Nicotinate-nucleotide 
pyrophosphorylase 
[carboxylating] (QPRTase) 
c, N,   Involved in the catabolism of quinolinate, an 
intermediate in the tryptophan-nicotinamide 
adenine dinucleotide pathway 
7 Q15274 
COP9 signalosome complex 
subunit 3 (COPS3) 
C, N Involved in various cellular and 
developmental processes 
1 Q9UNS2 
Serine/threonine-protein kinase 
PRKX 
C Belong to the protein kinase superfamily. 
AGC Ser/Thr protein kinase family. cAMP 
subfamily. A chromosomal aberration 
involving PRKX is a cause of sex reversal 
disorder  
1 P51817 
Caspase-6 [Precursor] C Involved in the activation cascade of 
caspases responsible for apoptosis execution. 
Overexpression promotes programmed cell 
death 
2 P55212 
Sushi, von Willebrand factor 
type A (SVEP1) 
Sec, PM  May play a role in the cell attachment 
process 
3 Q4LDE5 
Tubulin beta-2A chain cyto It binds two moles of GTP, one at an 
exchangeable site on the beta chain and one 
at a non-exchangeable site on the alpha-
chain 
1 Q13885 
Septin-7, CDC10 protein 
homolog 
c, cyto Cytokinesis 1 Q16181 
DnaJ homolog subfamily B 
member 6 (HSJ-2) 
C, PR, N Acts as an endogenous molecular chaperone 
for neuronal proteins including huntingtin 
1 O75190 
 
Table 1. List of PRMT6-interacting proteins identified by yeast two-hybrid screening. For each partner is shown 
the localization, the function the number of clones found with the Y2H and the Uniprot accession number. Figure 
legend for the cellular localization: N=Nucleus; C=Cytoplasm; M=Membrane; PM= Peripheral membrane protein; 
U=Ubiquitous; n=Nucleolus; m=Microsome; c=Cytosol; Mit=Mithocondrion; Sec=Secreted protein; PM=Plasma; 
cyto=Cytoskeleton; PR=Perinuclear region.   
 
 
4.2 Mapping the PRMT6 binding region  
 
To map the region of PRMT6 involved in the binding with its new putative partners, we did a series 
of deletion mutants cloned with PCR using pEG202-PRMT6 as a template.  
The methyltransferase domain is in the middle of the protein, between the amminoacid residues 86 
and 184. We decided to clone in pEG202 vector 4 mutants: (i) PRMT6 1-86: this mutant carries 
only the N-terminal region; (ii) PRMT6 1-184: which has the N-terminal region and the 
methyltransferase domain; (iii) PRMT6 87-375: with the methyltransferase domain and the C-
terminal region; and (iv) PRMT6 185-375: that carries only the C-terminal region (Figure 6). Each 
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deletion mutant was tested in yeast for its expression. They were all correctly expressed except for 
mutant 87-184 whose expression could not be detected and therefore was not used further (Figure 
7). 
 
 
   
Figure 6. Schematic representation of PRMT6 full length and delection mutants. These constructs were cloned 
with PCR in the pEG202 vector. The light blue box indicates the methyltransferase domain of the protein. 
 
 
 
Figure 7. Western blot assay of PRMT6 deletion mutant expressed in fusion with LexA in the pEG202 vector. 
SDS-PAGE of cellular lysates of the yeast strain EGY48/pSH18-34 transformed with each construct. For the western 
blot analysis, the antibody anti-LexA was used. The clone 87-184 does not express the fusion protein LexA-PRMT6 87-
184 (lanes 7-8). ODC is ornitine decarboxilase used as a negative control.   
 
After assaying their expression in yeast, 31 putative partners were tested in yeast two-hybrid assay 
for its ability to bind all these deletion constructs. Five proteins were not included in this screening, 
since they were considered not of interest from the biological point of view (four Proteasome 
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proteins, and the Heat shock 27kDa protein 1). PRMT6 full length was used as a positive control. 
ODC was used as a negative control and, as expected, no partners bound it (data not shown). 
Results are reported in Table 2.  
 
 
PARTNERS PRMT6 
 Full lenght 1-86 1-184 87-184 87-375 185-375 
Med28 + + + NA - - 
MTF2 + + + NA - - 
CDK5RAP3 + + + NA - - 
Nm23-H1 + + - NA - - 
EBP1 + + + NA - - 
NOB1 + + + NA - - 
UTP6 + + + NA - - 
hnRNP Q + - + NA - - 
GRSF-1 + + + NA - - 
CDK9 + + + NA - - 
SnRNP-B + + + NA - - 
PRPF39 + + + NA - - 
HYPK + - + NA - - 
PRDX4 + + + NA - - 
SAAL1 + + + NA - - 
FtL + + + NA - - 
MIF + + + NA - - 
HINT1 + + + NA - - 
HPRT1 + + + NA - - 
L38mt + + - NA - - 
LDH-B + - - NA - - 
FH + + + NA - - 
PTPS + + + NA - - 
QPRTase + + + NA - - 
COPS3  + + + NA - - 
PRKX + + + NA - - 
CASP6 + - + NA - - 
SVEP1 + + + NA - - 
TUBB2A + + + NA - - 
SEPT7 + + + NA - - 
HSJ-2 + + + NA - - 
PRMT6 + + + NA - - 
 
Table 2. Mapping of the interacting domain. Each partner was tested in two-hybrid assay for its ability to bind 5 
different deletion mutants. Mutant PRMT6 87-184 could not be used because it was not express in yeast, and it is 
reported as NA (Not Available). The + indicates the interaction. PRMT6 was added as a positive control; it is known, in 
fact, the ability of PRMT6 to bind and methylate itself (Frankel et al., 2002). 
 
These results show that, for most partners tested, the region of PRMT6 1-86 (the N-terminal region) 
seems to be necessary and sufficient for the binding. Only in some cases, we observe the necessity 
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of the presence of the region 1-184, consisting of both the N-terminal domain and the 
methyltransferase domain.  
 
 
4.3 Validation of Y2H results 
 
The GST Pull-down assay is an in vitro technique frequently used to confirm the direct interaction 
between two proteins. Here we decided to use this technique to confirm the binding between the 
putative partners found with the Y2H and PRMT6. To this end, the clones were tested for the direct 
interaction.  
We cloned all partners in fusion with HA tag in order to be used for in vitro translation (IVT). It is 
important to note that partners tested for the interaction with PRMT6 were not full length cDNAs, 
but were fragments of the proteins found out with the Y2H. These constructs were in vitro 
translated (IVT) and radiolabelled by incorporation of 35S Methionine. Proteins produced were then 
used for the GST pull-down assay. For this experiment we used the GST recombinant protein as 
negative control and the GST-PRMT6 as a positive control. In addition, we looked also if these 
proteins were partners in common with HMGA1b and HMGA2 proteins: in fact, we reasoned that it 
could be interesting to identify some new complexes, in which both PRMT6 and HMGA are 
involved. 
For eight of the 31 proteins tested (Med28, MTF2, UTP6, PRDX4, SAAL1, L38mt, LDH-B, and 
PRKX) it was not possible to obtain an IVT product. The remaining 23 proteins were assayed in 
GST-Pull down. For 4 proteins (Nm23-H1, GRSF-1, HYPK, and QPRTase) were not able to 
interact with PRMT6, probably, the binding to PRMT6 in yeast was mediated by another protein of 
the yeast. Alternatively, it could be that some PTMs are needed for the binding to occur. 
Instead, for 19 out of 23 partners, the interaction was confirmed. Of these 19 proteins, 8 were found 
to interact also with HMGA1b and HMGA2 (hnRNP Q, PRPF39, MIF, PTPS, COPS3, CASP6, 
SVEP1, and HSJ-2), and one protein (RNA binding protein NOB1) resulted to be a partner of 
PRMT6 and of HMGA2 but not of HMGA1b.  
Results are summarized in Figure 8 (panels a, and b) and in Table 3. 
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Figure 8. Validation of Y2H results by GST pull down assay. A. GST, GST-PRMT6, -HMGA1b, and -HMGA2 
were produced in bacteria, extracted and checked by SDS-PAGE for their correct production with Blu Coomassie 
Staining; B. Putative PRMT6 molecular partners were in vitro translated (IVT) and radiolabelled by incorporation of 
35S Methionine. GST pull-down assays were performed with GST, GST-PRMT6, -HMGA1b, and -HMGA2. For each 
partner, in lane 1 (input) a quantity corresponding to 20% of the IVT used in the GST pull-down experiments was 
loaded. Proteins are visualized by autoradiography.  
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PARTNERS GST Pull down 
 Comment PRMT6 HMGA1b HMGA2 
Med28 NA    
MTF2 NA    
CDK5RAP3  + - - 
Nm23-H1  - - - 
EBP1  + - - 
NOB1  + - + 
UTP6 NA    
hnRNP Q  + + + 
GRSF-1  - - - 
CDK9  + - - 
SnRNP-B  + - - 
PRPF39  + + + 
HYPK  - - - 
PRDX4 NA    
SAAL1 NA    
FtL  + - - 
MIF  + + + 
HINT1  + - - 
HPRT1  + - - 
L38mt NA    
LDH-B NA    
FH  + - - 
PTPS  + + + 
QPRTase  - - - 
COPS3   + + + 
PRKX NA    
CASP6  + + + 
SVEP1  + + + 
TUBB2A  + - - 
SEPT7  + - - 
HSJ-2  + + + 
 
Table 3. Table of GST Pull down results. For each partner tested, the confirmed interaction (+) with PRMT6, 
HMGA1b, and HMGA2, or the absence of binding (-) is reported. NA indicates that results are Not Available, since 
they could be not be in vitro translated. 
 
 
4.4 Confirm the interaction in vivo 
 
All proteins tested with GST Pull-down were in vivo assayed for their ability to bind PRMT6. The 
technique used to do it was the CoAffinity Purification (CoAP). In this assay, a protein “bait”, in 
our case PRMT6, is fused to the MBP (Maltose Binding Protein) tag, and the interaction with its 
putative partners, that is cloned in fusion with the HA tag, is revealed after purification with the 
Amylose resin.  
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In order to do it, PRMT6 was cloned in fusion with MBP in pcDNA3MBP vector and transfected in 
Hek293T cells.  
In the SDS-PAGE, for each protein, we loaded also a fraction of the total lysate and 5% of the input 
to verify that partners were produced and expressed in cells. 
Results show that only nine proteins were produced in cells (MTF2, Nm23-H1, NOB1, hnRNP Q, 
MIF, PTPS, CASP6, TUBB2A, and HSJ-2) and therefore could be tested for their interaction with 
PRMT6. Among these, seven resulted to interact with the enzyme (MTF2, Nm23-H1, NOB1, 
PTPS, CASP6, TUBB2A, and HSJ-2), while for the other two putative partners the interaction with 
PRMT6 could not be confirmed (hnRNP Q and MIF) (Figure 9).  
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Figure 9. In vivo interaction with PRMT6. Each partner fused to HA tag was tested for its ability to bind MBP- 
PRMT6 in vivo. Lysates of cells transfected with both the MBP PRMT6 vector and the HA partner were separated by 
SDS-PAGE and analyzed for their binding with PRMT6 by Western blot. The antibodies used for the analysis were 
anti-MBP, to check the correct expression of PRMT6 fused to this tag, and anti-HA to verify the binding of the partner 
to the MBP-fused protein. The empty vector with MBP was used as a negative control. To check the production and the 
expression of proteins in cells, both a fraction of total lysate and 5% of the input were loaded. The normalization of 
each protein was assessed with the Panceau staining. Cells used were Hek293T.   
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4.5 Identification of PRMT6 new substrates 
 
When a protein interacts with an enzyme, it can be either (i) its substrate, or (ii) a protein that, 
through this interaction, can modulate the enzyme function, or (iii) a protein modulated by the 
enzyme. To determine if proteins that are partners in common between PRMT6 and HMGA were 
also substrates of PRMT6, we did an in vitro methylation assay. In this analysis we included also 
two proteins, SnRNP B, and Tubulin beta, which are exclusively PRMT6 interactors. They were 
tested because, in a preliminary experiment, they resulted partners also for HMGA, but the 
association was not confirmed by further experiments.  
 
 
Figure 10. In vitro methylation assay of PRMT6 partners. Recombinant proteins in fusion with GST were incubated 
with radio-labelled S-Adenosyl Methionine (SAM) as a donor of methyl group for the in vitro methylation assay. 
Proteins were separated by SDS-PAGE and checked by autoradiography. To control the correct production and the 
amount of the protein Blue Comassie Staining was used (lower pannel). Stars (*) indicate the produced (in Blue 
Comassie gel) and methylated proteins (in the autoradiography). GAR was used as a positive control. 
 
 
All proteins were produced in bacteria, extracted and in vitro methylated using radio-labelled S-
Adenosyl Methionine (SAM) as a donor of methyl group. Four of the proteins tested (MIF, HSJ-2, 
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snRNP B, and TUBB2A) resulted in vitro methylated by PRMT6 (Figure 10). These proteins are 
new substrates of this enzyme. In Figure 10 it is also possible to note the automethylation activity of 
PRMT6 as a band of 85 kDa, that corresponds to its molecular weight.    
 
4.6 In vitro methylation assay in presence of HMGA 
 
To verify if the presence of HMGA1 protein could modulate the PRMT6 methylation, we 
performed an in vitro methylation assay in presence or absence of HMGA1a.  
It is known in literature (Sgarra et al., 2006) that PRMT6 methylates HMGA1a protein in residues 
R57 and R59, both in vivo and in vitro. First, we did an in vitro GST Pull-down to test if 
HMGA1aR57,59A, the double mutant in sites methylated by PRMT6, can bind the enzyme. As a 
negative control, we used the HMGA1a52 truncated form that is known that is not able to bind the 
methyltransferase. Results are reported in Figure 11.   
 
 
Figure 11. Test the binding between PRMT6 and HMGA1a mutants. Three different recombinant HMGA1a 
proteins (wild type, HMGA1a52, and HMGA1aR57,59A) were incubated with both GST alone and GST PRMT6. After  
Purification, proteins were separated by SDS-PAGE, and visualized by autoradiography. In the last three lanes 25 ng of 
each HMGA1a proteins were loaded. 
 
 
As reported in the Figure 11, both HMGA1a full length (wt), and HMGA1aR57,59A double mutant 
form, were able to bind GST PRMT6 but not GST alone (negative control). As expected, the 
truncated form HMGA1a52, lacking of the C-terminal domain, could not bind the enzyme.  
Consequently, we tested if the presence of HMGA proteins in the methylation reaction could 
modulate the PRMT6 action. 
For this pourpose, the in vitro methylation assay of MIF, HSJ-2, SnRNP-B, and TUBB2A, was then 
conducted in the presence of different amounts (0.5, 1, and 5 µg) of the three forms of HMGA 
proteins. For one substrate, MIF, the presence of HMGA protein in the mix reaction was relevant. 
Results 
62 
In fact, as reported in Figure 12, its methylation was enhanced in presence both of HMGA1a wt and 
of HMGA1aR57,59A form. In lane 1 and lane 9 of the figure, it is possible to see MIF’s 
methylation by PRMT6 in absence of HMGA1a. While, in lanes 2, 5, and 10 is reported its 
methylation in presence of HMGA1a wild type. In these lanes methylation’s signal appears 
stronger. This effect is visible also in the lanes in which the reaction was conduced in presence of 
HMGA1a double mutant (lanes 4, 7, and 12), but it is not so evident like previously. No significant 
effect is detectable for the methylation in presence of HMGA1a52 (lanes 3, 6, and 11). Lanes 8 and 
13 represents negative controls in which are reported the HMGA1a in vitro methylation assay 
without MIF: signals detected at 19 kDa represent HMGA1a methylation. In lane 12 the double 
mutant HMGA1a appears methylated, albeit at much lower level with respect to the wild type 
proteins. This is consistent with the presence of other low affinity methylation sites on HMGA1a 
protein (Sgarra et al., 2006). 
 
 
Figure 12. In vitro methylation of MIF in presence of HMGA1a proteins. Recombinant MIF protein in fusion with 
GST was incubated with radio-labelled S-Adenosyl Methionine (SAM) as a methyl group donor for the in vitro 
methylation assay. The experiment was conduced in the presence of various HMGA1a proteins in three different 
amount (0.5 µg, 1 µg, and 5 µg): the full length wild type form (lanes 2, 5, and 10), the HMGA1a52 truncated (lanes 3, 
6, and 11), and the HMGA1aR57,59A double mutant in residues methylated by PRMT6 (lanes 4, 7, and 12). Proteins 
were separated by SDS-PAGE and checked by autoradiography. To check the amount and the correct production, Blue 
Comassie Staining was used (not shown). Signals of PRMT6, MIF, and HMGA1a are reported. Stars (*) indicate GST 
degradation products. 
 
 
In this experiment, it is also visible the automethylation activity of PRMT6 (signals at 85 kDa).  
With this experiment we could demonstrate that the binding of HMGA1a proteins to PRMT6 has an 
increasing effect on the methylation of MIF. This effect is specific for this partner. In fact the same 
experiment conduced with the other substrates identified with this screening (HSJ-2 SnRNP B, and 
TUBB2A) showed not significant changes (data not shown). 
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4.7 Transcriptional activation of Cyclin A gene by MIF 
 
A paper reported a suppressor role played by MIF in the p53-dependent transcriptional activation of 
p21, Cyclin G, and in the induction of MDM2 (Hudson et al., 1999). Therefore, we asked if MIF 
could also have a role in the activation/repression of a Cyclin A reporter, a gene regulated by 
HMGA2 protein. To verify the cellular localization of MIF in cells we transfected a vector 
expressing GFP-MIF in Hek293T cells. Results obtained with this experiment confirmed data 
present in literature (Bach et al., 2009) that described MIF as a prevalent cytoplasmic protein, but 
with also a nuclear localization (data not shown). Once confirmed its cellular localization, we tested 
if the presence of MIF could have an effect on the Cyclin A promoter. We thus cloned the full 
length cDNA of human MIF (kindly provided by Dr. Roberta Maestro) in fusion with six myc tag 
in the pCS3MYC vector and cotransfected with a luciferase reporter gene under the cyclin A 
promoter. To normalize for transfection efficiencies, a vector expressing Renilla luciferase was 
included. Results are shown in Figure 13. MIF has an activating dose-dependent effect on this 
promoter (lanes 2 and 3). In fact, Hek293T cells transfected both with MIF and the Cyclin A 
promoter showed an increased level of transcription of the gene reporter up to 6 folds (lane 2). To 
test the possible effect of PRMT6 in the MIF’s effect on the Cyclin A promoter, we cotransfected 
also a PRMT6 expressing vector. PRMT6 effect on the Cyclin A promoter was an activation of 
about 5 folds of the reporter activity (Figure 13). In Figure 13, it is also shown that the 
cotransfection of PRMT6 caused a lower level of transcriptional activation by MIF. Further 
experiments are needed to better clarify the relationship between MIF and PRMT6 in the activation 
of the Cyclin A gene. 
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Figure 13. MIF overexpression activates the expression of the cyclin A gene. Hek293T cells were transiently 
cotrasfected with 1 µg of the luciferase reporter plasmid CycA (bars 1 to 6), 1.5 or 0.5 µg of the expression plasmid 
pcS3MYC MIF (bars 2 and 3 respectively), 1.5 or 0.5 µg of the expression plesmid pcDNA3HA PRMT6 (bars 4 and 5 
respectively), and 0.5 µg of both expression vectors pcS3MYC MIF and pcDNA3HA PRMT6 (bars 6). One hundred 
nanograms of pRL-CMV Renilla luciferase expression vector was included to normalize for transfection efficiencies. 
Values are reported as relative luciferase activity. Standard deviations are indicated for experiments repeated three 
times. The amounts of transfected MIF and PRMT6 in each sample were controlled by Western Blot (WB) analysis. 
MIF was revealed with an anti-MYC (α-MYC) antibody, while the amount of PRMT6 was controlled using an anti-HA 
(α-HA) antibody. The Tubulin γ and GAPDH levels show equivalent sample loadings. 
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5. DISCUSSION 
 
 
5.1 Yeast two-hybrid screening 
 
Until today very few information are available on PRMT6, its functions, and its molecular partners. 
To better characterize the biological function of this enzyme we decided to use the two-hybrid assay 
in yeast to look for new molecular partners of PRMT6. In fact, the identification of new interactors 
could allow to better define the molecular context in which the arginine methyltransferase is 
involved and to give a function also to the methylation of HMGA1a proteins, that is yet unknown.  
The two-hybrid screening was performed with a human fetal brain cDNA library. After both the 
primary and the secondary screening, 36 new putative partners resulted to interact with PRMT6. 
For their characteristic, we can divide them in four groups: (i) Transcription factors; (ii) 
ribonucleoproteins or proteins involved in RNA processing; (iii) proteins involved in the 
proteasome degradation; and (iv) others. These findings confirm the involvement of PRMT6 in 
gene transcription and RNA processing but extend it also to other processes. 
All these partners resulted to interact with the N-terminal portion of the PRMT6. This result is very 
peculiar: in fact all PRMTs are very similar in their sequence and in the structure of conserved 
domains. The main differences between various PRMTs are found in the N-terminal region; in fact, 
each PRMT has this part of different length (Zhang et al., 2000; Weiss et al., 2000; Bedford and 
Richard, 2005). Recent papers reported also some information about the N-terminal region of some 
PRMTs. For example, the human PRMT1 pre-mRNA can be alternatively spliced to yield three 
isoforms with distinct N-terminal sequences, and a biochemical characterization of these variants 
revealed that unique N-terminal sequences could influence catalytic activity as well as substrate 
specificity (Goulet et al., 2007). Also for PRMT8 is known the relevance of the N-terminal. In fact, 
the lacking of the initial 60 amino acid residues causes enhanced enzymatic activity, suggesting that 
this is the domain that can regulate the activity of the PRMT (Sayegh et al., 2007). Moreover, the 
N-terminal of PRMT8 contains the binding site for the EWS, an oncoprotein involved in Ewing 
sarcoma (Kim et al., 2008). With all these evidences we can hypothesize that even if all the PRMTs 
have the same structure, the specificity of the binding is provided by the N-terminal portion, and the 
different length of this part among the various arginine methyltransferases can give the specificity 
of the binding for a PRMT, and differentiate them from each other. 
 
 
Discussion 
66 
5.2 Validation of Y2H results 
      
The GST Pull-down is the technique chosen to confirm the results obtained with the yeast two-
hybrid and to verify the association between the partner and the enzyme. To extend the analysis also 
to the search of possible partners in common with HMGA proteins, we tested partners found in the 
previous screening for their ability to bind also HMGA1b and HMGA2. For this analyses we could 
not used the HMGA1a protein because this isoform could not be produced efficiently in bacteria.   
For these experiments were used partners which seemed more interesting, and for this reason 
proteins involved in the proteasome degradation and a heat shock protein were excluded. 
Among the 31 partners tested, for 19 the direct interaction was confirmed, and 8 out these resulted 
partners in common with HMGA1b and HMGA2. It is worthwhile to note that one protein, the 
RNA-binding protein NOB1, resulted to be partner exclusively of HMGA2, and did not associate 
with HMGA1b protein. This evidence is very important, because all partners known in literature 
until today are always in common between HMGA1 and HMGA2 proteins, and this is the first time 
that a protein can discriminate the binding between the two HMGA. It will be of interest to 
investigate more deeply on these common partners once this interaction will be confirmed in vivo as 
well. 
 
 
5.3 Confirm the interaction of PRMT6 partners in vivo 
 
To better characterize the interaction between PRMT6 and its partners we tested if this binding was 
possible also in vivo, using Hek293T cells. 
To demonstrate this, we used the CoAffinity Purification (CoAP) technique. Not all the partners 
tested were produced in cells. This is probably due to the fact that the cDNAs cloned with the Y2H 
were not full length and therefore only C-terminal fragments of the proteins were encoded and these 
were probably degraded easily within the cells. It could be tried to express them in fusion with a tag 
longer than the HA that could stabilize them or use the full length cDNAs. 
Among the nine proteins that were produced, seven resulted to interact also in vivo with PRMT6: 
MTF2, Nm23-H1, NOB1, PTPS, CASP6, TUBB2A, and HSJ-2. Possible causes for the lack of the 
binding for hnRNP Q and MIF can be several, including technical ones, since it is possible that 
specific buffer conditions might be needed for the binding to occur. 
It is important to note that the transfection of PRMT6 in cells seems to stabilize the expression of its 
partner Caspase-6. In fact, the signal relative to the cotransfection of PRMT6 and Casp-6 is higher 
than the ones relative to the Casp-6 alone. It could be that the presence of the enzyme either 
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stabilizes the Caspase or prevents its degradation. No papers are present in literature about Caspases 
proteins methylation. The only information regarding Caspase and methylation reported is the 
correlation between the CpG site promoter methylation and the down regulation of the protein, such 
us, for example, the Caspase-8. In fact, methylation of of CpG sites in the promoter region of the 
genes is known to transcriptionally repress these genes (Wu et al., 2010). With our experiments we 
could not produce Caspase-6 in bacteria, so we do not know if it is a substrate of PRMT6.  
If PRMT6 could methylate Caspase-6, it could be possible that this PTM stabilize the Caspase; 
Further experiments will be necessary to verify both if Caspase-6 is methylated by PRMT6 and if 
the stabilizing effect is due to its PTM. To ascertain it, we could use the inactive form of PRMT6 
mutated in the catalytic domain.   
Another possibility could be that, the effect of PRMT6 could be on some negative regulator of the 
Caspase-6, and for example, this regulator resulted methylated, was transcriptionally repressed and 
could not degrade the Caspase-6.  
With these experiments we could confirm several of the interactions found with the two-hybrid 
system in yeast also in a mammalian system. 
 
 
5.4 Identification of PRMT6 new substrates 
 
A protein interacting with PRMT6 can be either a substrate or a protein that through its binding can 
modulate the enzyme. To determine if partners in common between PRMT6 and HMGA are also 
substrates of PRMT6 we performed an in vitro methylation assay. For this analysis we used also 
two proteins (SnRNP B and Tubulin beta) that preliminary data indicated them as HMGA partners, 
but were not confirmed by further experiments. 
We were able to identify four new substrates of PRMT6: MIF, HSJ-2, snRNP B, and TUBB2A. 
Two of these proteins (MIF and HSJ-2) are also partners in common with HMGA1a and HMGA2 
proteins. 
 
Macrophage migration inhibitory factor (MIF)     
The macrophage migration inhibitory factor (MIF) was first characterized in 1966 as a molecule 
that inhibits the migration of macrophages (Bloom and Bennett al., 1966; Weiser et al., 1989), a 
role that inspired its name. Much research has been done since that time, yielding evidence that 
MIF primarily acts as a pro-inflammatory protein (Donn and Ray, 2004). For instance, it was shown 
that MIF acts not only on macrophages, but is also produced by these cells in response to 
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endotoxins, exotoxins, and cytokines, such as tumour necrosis factor-α and interferon-γ. In 
addition, it was demonstrated that neutralizing antibodies against MIF protects mice against septic 
shock (Bernhagen et al., 1993).  
Moreover MIF was shown to inactivate functionally the tumour suppressor p53, and in this way it 
may provide a link between inflammation and tumorigenesis (Hudson et al., 1999). Other recent 
papers showed novel roles for MIF: (i) it has a direct role in the up-regulation of Cyclooxygenase-2 
(COX-2) synthesis and Prostaglandin E2 (PGE2) secretion in ectopic endometrial cells. In fact MIF 
acts at more than one level to stimulate the synthesis of PGE2 and triggers the coordinate activation 
of multiple enzymes in the biosynthesis pathway (Carli et al., 2009); and (ii) MIF can bypass the 
growth arrest mediated by p53 in cells and suppress the transcriptional activation p53-dependent. In 
fact, the abundance of two p53 transcriptional targets, p21 and cyclin G, were decreased in cells 
MIF-treated with respect to the control (Hudson et al., 1999).  
Until today, only two PTMs of MIF are known: the phoshorylation of Tyr37 and the acetylation of 
Lys78. The function of these modifications are still unknown.  
In conclusion, this is the first time that MIF is shown methylated by an arginine protein 
methyltransferase. It is a new substrate of PRMT6.  
 
Human DnaJ homologue (HSJ-2) 
A human DnaJ homologue, HSJ-2, belongs to the DnaJ family of proteins and is a molecular 
chaperone (heat shock protein). Two different isoforms were characterized for HSJ-2: (i) HSJ-2a, 
that is 326 amino acids length, and (ii) HSJ-2b, that is 241 amino acids. Both proteins share the 
same N-terminal 231 amino acids, including the Dna J homology region (Hanai and Mashima, 
2003). It was reported that the large isoform of DNAJB6 is expressed at low levels in aggressive 
breast cancer cell lines. This protein regulates several key players in tumour formation and 
metastasis (such as the melanoma metastasis suppressor Kiss1), and it is functionally able to retard 
tumour growth (Mitra et al., 2008). HSJ-2 was shown to be present in both the cytoplasm and 
nucleus (Izawa et al., 2000) and throw its association with Hsp/c70 chaperone could play an 
important role in the regulation of the organization of actin filaments, microtubles, and vimentin 
filaments. Moreover it was speculated that it could exist some specific DnaJ/Hsp40 family proteins 
that link actin, tubulin, or various intermediate filaments proteins to Hsp/c70 (Izawa et al., 2000). 
Until today, about HSJ-2 post-translational modification known, only phosphorylation on Ser277 is 
reported (Olsen et al., 2006). Our results show for the first time that HSJ-2 protein can be in vitro 
methylated by PRMT6.   
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Small nuclear ribonucleoprotein-associated proteins B and B’ (SnRNP B) 
The small nuclear ribonucleoprotein-associated proteins B and B’ (also called snRNP B or Sm 
protein B/B’) associates both with others Sm proteins (D1, D2, D3, E, F, and G) and with snRNP 
U1, U2, U4/U6, and U5 to form the Sm core of the spliceosome, and may have a functional role in 
the pre-mRNA splicing (Luhrmann et al., 1990). The seven Sm core proteins assemble with 
snRNAs containing a Sm sequence motif in the cytoplasm (Branlant et al., 1982). Newly 
synthesized snRNP proteins are stored in pools of partially assembled RNA-free complexes (Raker 
et al., 1996). Hypermethylation of the m7G cap of the snRNAs requires a proper assembly of the 
Sm proteins on the U1, U2, U4, and U5 snRNAs (Plessel et al., 1994). The snRNP is then imported 
into the nucleus. It has been shown that PRMT5 can symmetrically methylate SnRNP B (Meister et 
al., 2001), but Miranda and co-worker showed that Sm B/B’ purified from nuclear fractions contain 
asymmetric ω-NG,NG-dimehtylarginine residues in addition to the already reported symmetric 
dimethylarginine residues (Miranda et al., 2004). It is known that PRMT5 can methylate in a 
symmetric way, so PRMT6 could be the enzyme responsible for that asymmetric methylation. In 
fact, it is the first time that SnRNP B was shown to be methylated by PRMT6. 
 
Tubulin beta-2A chain (TUBB2A) 
Tubulin is the major constituent of microtubules. In immunohystochemical analyses its localization 
is prevalently cytoplasmic, but in a proteomic study using 2D-gel electrophoresis and mass 
spectrometry, the tubulin beta chain was identified as being nuclear associated. Its nuclear 
localization is considered an example of the dynamic behaviour in the nucleus, for whose some 
proteins can be imported/exported by nucleus to cytoplasm and vice versa (Bergquist et al., 2001).  
About the presence of post-translational modifications in tubulin beta proteins, the first paper 
reporting methylation in the C-terminal portion of both α- and β-tubulin is very recent and it is by 
Weiss group. Studying the genome of the Toxoplasma gondii, an obligate intracellular parasite and 
an important human pathogen, they show that the tubulin is extensively altered by specific pos-
translation modifications, such as acetylation, polyglutamylation, and methylation. They did not 
identify protein’s residues methylated (Xiao et al., 2010).      
 
In vivo methylation data are needed to conclusively demonstrate that these proteins are in vivo 
substrates for PRMT6, but the fact that for two of them (HSJ-2 and TUBB2A) we show that could 
in vivo associate with PRMT6 constitute an additional evidence. 
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5.5 HMGA1a modulates MIF’s methylation 
 
The presence, in the reaction mix, of either HMGA1a full length or HMGA1aR57,59A double 
mutant, but not of the delection mutant HMGA1a52, causes a difference in the in vitro methylation 
of MIF by PRMT6. HMGA1a is a known substrate of PRMT6 (Sgarra et al., 2006); in fact, the 
enzyme methylates both in vitro and in vivo the arginine residues R57 and R59 of HMGA1a 
protein. With our experiments we found that for one PRMT6 substrate, MIF, the presence of 
HMGA has a relevant effect. In fact, in vitro methylation is enhanced in presence both of HMGA1a 
full length and the double mutant. We speculate that the effect is due by the binding of the HMGA 
to PRMT6; in fact there are no changes when the HMGA1a deletion mutant that cannot bind the 
enzyme is included in the in vitro methylation assay.  
Adding another substrate, in this case HMGA1a wild type, to the reaction mix, could have caused a 
decrease in MIF’s methylation due to the competition of another substrate for the same enzyme. 
Using a double mutant of HMGA1a that cannot be methylated but was still able to bind PRMT6 
allowed us to circumvent this problem. 
Now it could be interesting to better characterize both the function of HMGA in relationship to 
PRMT6, and the function of MIF in the cells. In fact, we could have discovered a new 
“enhanceosome”, a complex of two or more proteins that co-operate in a function involved in gene 
expression. It is already known from literature that HMGA1a participates to the enhanceosome of 
the human gene virus-inducible IFN-β and, through its binding to some regulatory sequences, 
causes changes in the DNA that allow the binding of transcription factors (Yie et al., 1999). 
Therefore, it could be interesting both to understand if there are genes for which MIF can act as an 
inductor/repressor and to characterize if the presence of HMGA in this context changes the MIF’s 
effect. 
  
 
5.6 MIF activates the Cyclin A promoter transcription 
 
In 1999 it was demonstrated that MIF acts as suppressor both for the transcriptional activity of p53 
and for some of its reporter genes (p21, Cyclin G, and MDM2) (Hudson et al., 1999). 
Looking for a role for MIF in relation with HMGA proteins, we checked if it could enhance/repress 
a gene which is a known target of HMGA2. For this experiment we choose the promoter of the 
Cyclin A, whose transcription is enhanced in presence of HMGA2 protein (Tessari et al., 2003). 
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With our preliminary experiments we could demonstrate an effect of MIF on Cyclin A promoter. In 
fact, the transcription of the reporter gene appears enhanced in the presence of MIF, and this 
activation seems to be dose-dependent. In addition we demonstrated that also PRMT6 is able to 
activate the same reporter gene. It is worthwhile to note that the presence of both MIF and PRMT6 
cotransfected in cells results in a lower activation of the CycA promoter. It could be that the 
methylation of PRMT6 on MIF has a negative effect on MIF’s function, but to ascertain it, further 
experiments will be necessary. For example it could be used the inactive form of PRMT6 mutated 
in the catalytic domain. 
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6. CONCLUSIONS 
 
 
In the last years the study and characterization of protein post translational modifications (PTMs) 
are becoming increasingly important. In fact, they can determine/modulate the stability of a protein, 
its folding, conformation, distribution, localization, turnover, and interaction with DNA or other 
proteins. Among the various PTMs known, methylation is the most recently discovered and can 
involve both arginine and lysine residues. It has been predicted that over 1% of genes in the 
mammalian genome encode methyltransferase, and to date there are at least 4 cellular processes that 
are regulated by arginine methylation: transcriptional regulation, RNA processing, 
nucleus/cytoplasm shuttling, and DNA repair. Until today, nine mammalian protein arginine 
methyltransferases (PRMTs) are known (PRMT1-9). Among these, PRMT6 has a predominantly 
nuclear localization and it can methylate itself. Very few information about PRMT6 are known. 
This enzyme has been involved in the pathogenesis of the HIV virus, in DNA repair processes, and, 
more recently, in the regulation of transcription and alternative splicing. In addition of PRMT6 
itself, there are only other six substrates. Among these, three are HIV proteins: Tat, Rev, and 
Nucleocapsid proteins. Other PRMT6 substrates are DNA Polymerase β, Histone H3, and 
HMGA1a protein.  
With this study we could expand the knowledge about PRMT6, discovering 36 new partners and 
also 4 new substrates (MIF, HSJ-2, snRNP B, and TUBB2A). This is very useful to understand the 
context in which PRMT6 acts, and the putative pathways in which it could be involved, since this 
enzyme is poorly characterized.   
In addition since in our laboratory it was previously demonstrated that HMGA1a is in vivo 
methylated by PRMT6, we looked also for partners in common with HMGA that together, could 
constitute complexes regulating different processes. For one PRMT6 substrate, MIF, we conduced 
more investigations to clarify a possible role for its methylation. We demonstrated that the presence 
of HMGA1a protein could enhance in vitro the methylation of MIF. 
Moreover, using a reporter gene known to be activated in the presence of HMGA2, the Cyclin A 
promoter (CycA), we could demonstrate that the presence of PRMT6 had a negative effect on 
MIF’s activation. In fact, we showed that MIF could activate the transcription of the CycA 
promoter in a dose-dependent manner; on the contrary, although PRMT6 had an activating effect on 
this promoter, the simultaneous presence of PRMT6 and MIF resulted in a lower promoter 
Conclusions 
73 
activation, Since HMGA is also a MIF partner, further experiments will be needed to better 
characterize if there is a relation between PRMT6, MIF, and HMGA protein. 
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